{
  "doc_id": "32",
  "paragraphs": [
    {
      "paragraph_id": "0",
      "paragraph": "中国慢性肾脏病患者合并高尿酸血症诊治专家共识",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "中国慢性肾脏病患者合并高尿酸血症诊治专家共识",
          "start_idx": 0,
          "end_idx": 22,
          "entities": [
            {
              "entity_id": "T0",
              "entity": "高尿酸血症",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 16,
              "entity_en": "Hyperuricemia"
            },
            {
              "entity_id": "T1",
              "entity": "慢性肾脏病",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7,
              "entity_en": "Chronic kidney disease"
            },
            {
              "entity_id": "T2",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 4,
              "end_idx": 6,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R0",
              "head_entity_id": "T2",
              "tail_entity_id": "T1"
            }
          ],
          "sentence_en": "Expert consensus on the diagnosis and treatment of chronic kidney disease patients with hyperuricemia in China"
        }
      ],
      "paragraph_en": "Expert consensus on the diagnosis and treatment of chronic kidney disease patients with hyperuricemia in China"
    },
    {
      "paragraph_id": "1",
      "paragraph": "前言",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "前言",
          "start_idx": 0,
          "end_idx": 2,
          "entities": [],
          "relations": [],
          "sentence_en": "Preface"
        }
      ],
      "paragraph_en": "Preface"
    },
    {
      "paragraph_id": "2",
      "paragraph": "慢性肾脏病(chronic kidney disease，CKD)已成为全球性重要公共卫生问题，中国流行病学研究显示，我国普通人群CKD的患病率为10.8%，中国南方地区普通人群为12.1%，农村地区为13.6%，高原地区藏族人群为19.1%，北方地区普通人群为16.9%。CKD持续进展至终末期肾病(end stage renal disease，ESRD)会严重影响患者的生存和生活质量。ESRD所需的医疗费用也对国家、社会和患者家庭造成巨大的经济负担。寻找可控的危险因素进而采取针对性措施对于延缓CKD的持续进展非常重要。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "慢性肾脏病(chronic kidney disease，CKD)已成为全球性重要公共卫生问题，中国流行病学研究显示，我国普通人群CKD的患病率为10.8%，中国南方地区普通人群为12.1%，农村地区为13.6%，高原地区藏族人群为19.1%，北方地区普通人群为16.9%。CKD持续进展至终末期肾病(end stage renal disease，ESRD)会严重影响患者的生存和生活质量。",
          "start_idx": 0,
          "end_idx": 196,
          "entities": [
            {
              "entity_id": "T3",
              "entity": "慢性肾脏病(chronic kidney disease，CKD)",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 33,
              "entity_en": "Chronic kidney disease (CKD)"
            },
            {
              "entity_id": "T4",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 65,
              "end_idx": 68,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T5",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 137,
              "end_idx": 140,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T6",
              "entity": "终末期肾病(end stage renal disease，ESRD)",
              "entity_type": "Disease",
              "start_idx": 145,
              "end_idx": 180,
              "entity_en": "End stage renal disease (ESRD)"
            },
            {
              "entity_id": "T9",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 2,
              "end_idx": 4,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T10",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 148,
              "end_idx": 149,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T11",
              "entity": "终末期",
              "entity_type": "Class",
              "start_idx": 145,
              "end_idx": 148,
              "entity_en": "Terminal stage"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R1",
              "head_entity_id": "T9",
              "tail_entity_id": "T3"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R2",
              "head_entity_id": "T10",
              "tail_entity_id": "T6"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R3",
              "head_entity_id": "T11",
              "tail_entity_id": "T6"
            }
          ],
          "sentence_en": "Chronic kidney disease (CKD) has become an important global public health issue. Epidemiological studies in China show that the prevalence of CKD in the general population is 10.8%, 12.1% in the general population in southern China, 13.6% in rural areas, 19.1% in Tibetans in plateau areas, and 16.9% in the general population in northern China. The continued progression of CKD to end-stage renal disease (ESRD) will seriously affect the survival and quality of life of patients."
        },
        {
          "sentence_id": "1",
          "sentence": "ESRD所需的医疗费用也对国家、社会和患者家庭造成巨大的经济负担。",
          "start_idx": 196,
          "end_idx": 229,
          "entities": [
            {
              "entity_id": "T7",
              "entity": "ESRD",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "ESRD"
            }
          ],
          "relations": [],
          "sentence_en": "The medical expenses required for ESRD also impose a huge economic burden on the country, society and patients' families."
        },
        {
          "sentence_id": "2",
          "sentence": "寻找可控的危险因素进而采取针对性措施对于延缓CKD的持续进展非常重要。",
          "start_idx": 229,
          "end_idx": 264,
          "entities": [
            {
              "entity_id": "T8",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 22,
              "end_idx": 25,
              "entity_en": "CKD"
            }
          ],
          "relations": [],
          "sentence_en": "Finding controllable risk factors and taking targeted measures is very important to slow down the continued progression of CKD."
        }
      ],
      "paragraph_en": "Chronic kidney disease (CKD) has become an important global public health issue. Epidemiological studies in China show that the prevalence of CKD in the general population is 10.8%, 12.1% in the general population in southern China, 13.6% in rural areas, 19.1% in Tibetans in plateau areas, and 16.9% in the general population in northern China. The continued progression of CKD to end-stage renal disease (ESRD) will seriously affect the survival and quality of life of patients. The medical expenses required for ESRD also impose a huge economic burden on the country, society, and patients' families. Finding controllable risk factors and then taking targeted measures is very important to delay the continued progression of CKD."
    },
    {
      "paragraph_id": "3",
      "paragraph": "我国CKD患者中的高尿酸血症(hyperuricemia，HUA)患病率为36.6%~50.0%，随CKD的进展其患病率明显升高。在IgA肾病患者队列中的研究显示，HUA是肾功能进展的独立危险因素，且该作用独立于患者的基线eGFR水平。维持性腹膜透析(腹透)患者的队列研究显示，血尿酸水平与腹透患者的全因死亡及心血管疾病(cardiovascular disease，CVD)死亡均独立相关。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "我国CKD患者中的高尿酸血症(hyperuricemia，HUA)患病率为36.6%~50.0%，随CKD的进展其患病率明显升高。在IgA肾病患者队列中的研究显示，HUA是肾功能进展的独立危险因素，且该作用独立于患者的基线eGFR水平。维持性腹膜透析(腹透)患者的队列研究显示，血尿酸水平与腹透患者的全因死亡及心血管疾病(cardiovascular disease，CVD)死亡均独立相关。",
          "start_idx": 0,
          "end_idx": 196,
          "entities": [
            {
              "entity_id": "T12",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 5,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T13",
              "entity": "高尿酸血症(hyperuricemia，HUA)",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 33,
              "entity_en": "Hyperuricemia (HUA)"
            },
            {
              "entity_id": "T14",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 50,
              "end_idx": 53,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T15",
              "entity": "IgA肾病",
              "entity_type": "Disease",
              "start_idx": 66,
              "end_idx": 71,
              "entity_en": "IgA nephropathy"
            },
            {
              "entity_id": "T16",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 82,
              "end_idx": 85,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T17",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 111,
              "end_idx": 115,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T18",
              "entity": "维持性腹膜透析(腹透)",
              "entity_type": "Treatment",
              "start_idx": 118,
              "end_idx": 129,
              "entity_en": "Maintenance peritoneal dialysis (MPD)"
            },
            {
              "entity_id": "T19",
              "entity": "血尿酸",
              "entity_type": "Test_items",
              "start_idx": 139,
              "end_idx": 142,
              "entity_en": "Serum uric acid"
            },
            {
              "entity_id": "T20",
              "entity": "腹透",
              "entity_type": "Treatment",
              "start_idx": 145,
              "end_idx": 147,
              "entity_en": "Peritoneal dialysis"
            },
            {
              "entity_id": "T21",
              "entity": "心血管疾病(cardiovascular disease，CVD)",
              "entity_type": "Disease",
              "start_idx": 155,
              "end_idx": 188,
              "entity_en": "Cardiovascular disease (CVD)"
            },
            {
              "entity_id": "T22",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 155,
              "end_idx": 158,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T23",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 69,
              "end_idx": 70,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R4",
              "head_entity_id": "T23",
              "tail_entity_id": "T15"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R5",
              "head_entity_id": "T17",
              "tail_entity_id": "T16"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R6",
              "head_entity_id": "T19",
              "tail_entity_id": "T21"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R7",
              "head_entity_id": "T22",
              "tail_entity_id": "T21"
            }
          ],
          "sentence_en": "The prevalence of hyperuricemia (HUA) in CKD patients in my country is 36.6%~50.0%, and its prevalence increases significantly with the progression of CKD. Studies in a cohort of patients with IgA nephropathy have shown that HUA is an independent risk factor for renal function progression, and this effect is independent of the patient's baseline eGFR level. A cohort study of patients on maintenance peritoneal dialysis (PD) showed that serum uric acid levels were independently associated with all-cause mortality and cardiovascular disease (CVD) mortality in PD patients."
        }
      ],
      "paragraph_en": "The prevalence of hyperuricemia (HUA) in CKD patients in my country is 36.6%~50.0%, and its prevalence increases significantly with the progression of CKD. Studies in a cohort of patients with IgA nephropathy have shown that HUA is an independent risk factor for renal function progression, and this effect is independent of the patient's baseline eGFR level. A cohort study of patients on maintenance peritoneal dialysis (PD) showed that serum uric acid levels were independently associated with all-cause mortality and cardiovascular disease (CVD) mortality in PD patients."
    },
    {
      "paragraph_id": "4",
      "paragraph": "然而，目前对于CKD患者中无症状HUA的治疗仍存在争议。我们需要基于目前已有的证据和经验，制定符合中国CKD患者实际情况的专家共识，指导临床医生关注和重视CKD患者HUA的诊断和治疗，并为将来制定临床指南提供基础。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "然而，目前对于CKD患者中无症状HUA的治疗仍存在争议。",
          "start_idx": 0,
          "end_idx": 28,
          "entities": [
            {
              "entity_id": "T24",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T25",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 16,
              "end_idx": 19,
              "entity_en": "HUA"
            }
          ],
          "relations": [],
          "sentence_en": "However, the treatment of asymptomatic HUA in CKD patients remains controversial."
        },
        {
          "sentence_id": "1",
          "sentence": "我们需要基于目前已有的证据和经验，制定符合中国CKD患者实际情况的专家共识，指导临床医生关注和重视CKD患者HUA的诊断和治疗，并为将来制定临床指南提供基础。",
          "start_idx": 28,
          "end_idx": 107,
          "entities": [
            {
              "entity_id": "T26",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 23,
              "end_idx": 26,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T27",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 49,
              "end_idx": 52,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T28",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 54,
              "end_idx": 57,
              "entity_en": "HUA"
            }
          ],
          "relations": [],
          "sentence_en": "We need to develop an expert consensus based on the current evidence and experience that conforms to the actual situation of Chinese CKD patients, guide clinicians to pay attention to and attach importance to the diagnosis and treatment of HUA in CKD patients, and provide a basis for the formulation of clinical guidelines in the future."
        }
      ],
      "paragraph_en": "However, the treatment of asymptomatic HUA in CKD patients is still controversial. We need to develop an expert consensus based on the current evidence and experience that conforms to the actual situation of Chinese CKD patients, guide clinicians to pay attention to and attach importance to the diagnosis and treatment of HUA in CKD patients, and provide a basis for the formulation of clinical guidelines in the future."
    },
    {
      "paragraph_id": "5",
      "paragraph": "证据来源",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "证据来源",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": [],
          "sentence_en": "Sources of evidence"
        }
      ],
      "paragraph_en": "Sources of evidence"
    },
    {
      "paragraph_id": "6",
      "paragraph": "1.证据来源：本共识以关键词检索当前关CKD合并HUA的相关研究证据，主要关键词包括：慢性肾脏病(chronic kidney disease)、高尿酸血症(hyperuricemia)、指南(guideline)、荟萃分析(met中国生物医学文献数据库(CBM)、中国期刊网全文数据库(CNKI)、万方数据资源系统和中文科技期刊全文数据库(VIP)。检索时间从建库至2016年8月底。同时检索医脉通、Uptodate、Dynamed补充指南和相关入研究，查看纳入研究的参考文献。若缺乏指南和系统评价证剧支持，则选用随机对照试验(RCT)，若RCT缺乏，则补充观察性研究和综述。见图1。a analysis)、系统评价(systemic review)、随机对照试验(randomized controlled trial)。检索数据库包括：Embase、Medline PubMed、循证医学数据库(包括CDSR DARE、CCTR及ACP Journal Club)、OVID平台数据库、Springer—Link、Elsevier ScienceDirect电子期刊、",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.证据来源：本共识以关键词检索当前关CKD合并HUA的相关研究证据，主要关键词包括：慢性肾脏病(chronic kidney disease)、高尿酸血症(hyperuricemia)、指南(guideline)、荟萃分析(met中国生物医学文献数据库(CBM)、中国期刊网全文数据库(CNKI)、万方数据资源系统和中文科技期刊全文数据库(VIP)。",
          "start_idx": 0,
          "end_idx": 176,
          "entities": [
            {
              "entity_id": "T29",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 19,
              "end_idx": 22,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T30",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 27,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T31",
              "entity": "慢性肾脏病(chronic kidney disease)",
              "entity_type": "Disease",
              "start_idx": 43,
              "end_idx": 72,
              "entity_en": "Chronic kidney disease"
            },
            {
              "entity_id": "T32",
              "entity": "高尿酸血症(hyperuricemia)",
              "entity_type": "Disease",
              "start_idx": 73,
              "end_idx": 93,
              "entity_en": "Hyperuricemia"
            },
            {
              "entity_id": "T33",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 45,
              "end_idx": 47,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R8",
              "head_entity_id": "T33",
              "tail_entity_id": "T31"
            }
          ],
          "sentence_en": "1. Source of evidence: This consensus uses keywords to search for current research evidence related to CKD combined with HUA. The main keywords include: chronic kidney disease, hyperuricemia, guideline, meta-analysis, and Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Wanfang Data Resource System, and Chinese Science and Technology Journal Database (VIP)."
        },
        {
          "sentence_id": "1",
          "sentence": "检索时间从建库至2016年8月底。",
          "start_idx": 176,
          "end_idx": 193,
          "entities": [],
          "relations": [],
          "sentence_en": "The retrieval period was from the establishment of the database to the end of August 2016."
        },
        {
          "sentence_id": "2",
          "sentence": "同时检索医脉通、Uptodate、Dynamed补充指南和相关入研究，查看纳入研究的参考文献。",
          "start_idx": 193,
          "end_idx": 240,
          "entities": [],
          "relations": [],
          "sentence_en": "At the same time, we searched Yimaitong, Uptodate, Dynamed supplementary guidelines and related included studies, and checked the references of included studies."
        },
        {
          "sentence_id": "3",
          "sentence": "若缺乏指南和系统评价证剧支持，则选用随机对照试验(RCT)，若RCT缺乏，则补充观察性研究和综述。",
          "start_idx": 240,
          "end_idx": 289,
          "entities": [],
          "relations": [],
          "sentence_en": "If there is a lack of evidence from guidelines and systematic reviews, randomized controlled trials (RCTs) should be used. If RCTs are lacking, observational studies and reviews should be used as supplements."
        },
        {
          "sentence_id": "4",
          "sentence": "见图1。",
          "start_idx": 289,
          "end_idx": 293,
          "entities": [],
          "relations": [],
          "sentence_en": "See Figure 1."
        },
        {
          "sentence_id": "5",
          "sentence": "a analysis)、系统评价(systemic review)、随机对照试验(randomized controlled trial)。",
          "start_idx": 293,
          "end_idx": 363,
          "entities": [],
          "relations": [],
          "sentence_en": "a analysis), systematic review, and randomized controlled trial."
        },
        {
          "sentence_id": "6",
          "sentence": "检索数据库包括：Embase、Medline PubMed、循证医学数据库(包括CDSR DARE、CCTR及ACP Journal Club)、OVID平台数据库、Springer—Link、Elsevier ScienceDirect电子期刊、",
          "start_idx": 363,
          "end_idx": 487,
          "entities": [],
          "relations": [],
          "sentence_en": "The search databases include: Embase, Medline PubMed, Evidence-Based Medicine Database (including CDSR DARE, CCTR and ACP Journal Club), OVID platform database, Springer-Link, Elsevier ScienceDirect electronic journals,"
        }
      ],
      "paragraph_en": "1. Source of evidence: This consensus uses keywords to search for current research evidence on CKD combined with HUA. The main keywords include: chronic kidney disease, hyperuricemia, guideline, meta-analysis (meta-analysis), systematic review, and randomized controlled trial. The search databases include: Embase, Medline PubMed, Evidence-Based Medicine Database (including CDSR DARE, CCTR and ACP Journal Club), OVID platform database, Springer-Link, Elsevier ScienceDirect electronic journals,"
    },
    {
      "paragraph_id": "7",
      "paragraph": "2.纳入、排除标准：纳入所有CKD合并HUA相关的研究，研究类型包括指南、系统评价、观察性研究、综述。部分研究作为支撑推荐意见的相关证据，部分研究作为提供参考的背景材料。未纳入非中、英文发表的研究和摘要。见图1。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.纳入、排除标准：纳入所有CKD合并HUA相关的研究，研究类型包括指南、系统评价、观察性研究、综述。",
          "start_idx": 0,
          "end_idx": 51,
          "entities": [
            {
              "entity_id": "T34",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 14,
              "end_idx": 17,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T35",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 19,
              "end_idx": 22,
              "entity_en": "HUA"
            }
          ],
          "relations": [],
          "sentence_en": "2. Inclusion and exclusion criteria: All studies related to CKD combined with HUA were included, including guidelines, systematic reviews, observational studies, and reviews."
        },
        {
          "sentence_id": "1",
          "sentence": "部分研究作为支撑推荐意见的相关证据，部分研究作为提供参考的背景材料。",
          "start_idx": 51,
          "end_idx": 85,
          "entities": [],
          "relations": [],
          "sentence_en": "Some studies serve as relevant evidence to support the recommendations, and some studies serve as background material for reference."
        },
        {
          "sentence_id": "2",
          "sentence": "未纳入非中、英文发表的研究和摘要。",
          "start_idx": 85,
          "end_idx": 102,
          "entities": [],
          "relations": [],
          "sentence_en": "Studies and abstracts published in languages other than Chinese or English were not included."
        },
        {
          "sentence_id": "3",
          "sentence": "见图1。",
          "start_idx": 102,
          "end_idx": 106,
          "entities": [],
          "relations": [],
          "sentence_en": "See Figure 1."
        }
      ],
      "paragraph_en": "2. Inclusion and exclusion criteria: All studies related to CKD combined with HUA were included, including guidelines, systematic reviews, observational studies, and reviews. Some studies were used as relevant evidence to support recommendations, and some studies were used as background materials for reference. Studies and abstracts published in languages other than Chinese or English were not included. See Figure 1."
    },
    {
      "paragraph_id": "8",
      "paragraph": "3.方法学质量评价：对检索到的文献进行质量评价，其中对指南使用AGREE II工具，对系统评价使用AMSTAR工具，对RCT使用Cochrane Risk of Bias工具，对观察性研究使用对应的方法学质量评价工具。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.方法学质量评价：对检索到的文献进行质量评价，其中对指南使用AGREE II工具，对系统评价使用AMSTAR工具，对RCT使用Cochrane Risk of Bias工具，对观察性研究使用对应的方法学质量评价工具。",
          "start_idx": 0,
          "end_idx": 109,
          "entities": [],
          "relations": [],
          "sentence_en": "3. Methodological quality assessment: The quality of the retrieved literature was assessed using the AGREE II tool for guidelines, the AMSTAR tool for systematic reviews, the Cochrane Risk of Bias tool for RCTs, and the corresponding methodological quality assessment tools for observational studies."
        }
      ],
      "paragraph_en": "3. Methodological quality assessment: The quality of the retrieved literature was assessed using the AGREE II tool for guidelines, the AMSTAR tool for systematic reviews, the Cochrane Risk of Bias tool for RCTs, and the corresponding methodological quality assessment tools for observational studies."
    },
    {
      "paragraph_id": "9",
      "paragraph": "诊断标准和分型",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "诊断标准和分型",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": [],
          "sentence_en": "Diagnostic criteria and classification"
        }
      ],
      "paragraph_en": "Diagnostic criteria and classification"
    },
    {
      "paragraph_id": "10",
      "paragraph": "1.CKD的诊断标准和分期：CKD的诊断标准：①肾脏损伤(肾脏结构或功能异常)≥3个月，伴或不伴肾小球滤过率(GFR)下降，肾脏病理学检查异常或肾脏损伤(血、尿成分或影像学检查异常)；②GFR<60ml·min-1·1.73m2)-1达到或超过3个月，有或无肾脏损伤证据。CKD的分期参考改善全球肾脏病预后组织(The Kidney Disease：Improving Global Outcomes，KDIGO)的标准。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.CKD的诊断标准和分期：CKD的诊断标准：①肾脏损伤(肾脏结构或功能异常)≥3个月，伴或不伴肾小球滤过率(GFR)下降，肾脏病理学检查异常或肾脏损伤(血、尿成分或影像学检查异常)；②GFR<60ml·min-1·1.73m2)-1达到或超过3个月，有或无肾脏损伤证据。",
          "start_idx": 0,
          "end_idx": 136,
          "entities": [
            {
              "entity_id": "T36",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 5,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T37",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 14,
              "end_idx": 17,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T38",
              "entity": "肾小球滤过率(GFR)",
              "entity_type": "Test_items",
              "start_idx": 48,
              "end_idx": 59,
              "entity_en": "Glomerular filtration rate (GFR)"
            },
            {
              "entity_id": "T39",
              "entity": "下降",
              "entity_type": "Test_Value",
              "start_idx": 59,
              "end_idx": 61,
              "entity_en": "decline"
            },
            {
              "entity_id": "T40",
              "entity": "肾脏病理学检查",
              "entity_type": "Test",
              "start_idx": 62,
              "end_idx": 69,
              "entity_en": "Renal pathology examination"
            },
            {
              "entity_id": "T41",
              "entity": "血、尿成分或影像学检查",
              "entity_type": "Test",
              "start_idx": 77,
              "end_idx": 88,
              "entity_en": "Blood, urine, or imaging tests"
            },
            {
              "entity_id": "T42",
              "entity": "GFR",
              "entity_type": "Test_items",
              "start_idx": 93,
              "end_idx": 96,
              "entity_en": "GFR"
            },
            {
              "entity_id": "T43",
              "entity": "<60ml·min-1·1.73m2)-1",
              "entity_type": "Test_Value",
              "start_idx": 96,
              "end_idx": 117,
              "entity_en": "<60ml·min-1·1.73m2)-1"
            },
            {
              "entity_id": "T44",
              "entity": "达到或超过3个月",
              "entity_type": "Test_Value",
              "start_idx": 117,
              "end_idx": 125,
              "entity_en": "3 months or more"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_Disease",
              "relation_id": "R9",
              "head_entity_id": "T40",
              "tail_entity_id": "T36"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R10",
              "head_entity_id": "T41",
              "tail_entity_id": "T36"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R11",
              "head_entity_id": "T38",
              "tail_entity_id": "T36"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R12",
              "head_entity_id": "T38",
              "tail_entity_id": "T37"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R13",
              "head_entity_id": "T40",
              "tail_entity_id": "T37"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R14",
              "head_entity_id": "T41",
              "tail_entity_id": "T37"
            }
          ],
          "sentence_en": "1. Diagnostic criteria and staging of CKD: Diagnostic criteria for CKD: ① Kidney damage (abnormal kidney structure or function) ≥ 3 months, with or without decreased glomerular filtration rate (GFR), abnormal kidney pathology examination or kidney damage (abnormal blood, urine components or imaging examinations); ② GFR < 60 ml·min-1·1.73 m2)-1 for 3 months or more, with or without evidence of kidney damage."
        },
        {
          "sentence_id": "1",
          "sentence": "CKD的分期参考改善全球肾脏病预后组织(The Kidney Disease：Improving Global Outcomes，KDIGO)的标准。",
          "start_idx": 136,
          "end_idx": 211,
          "entities": [
            {
              "entity_id": "T45",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "CKD"
            }
          ],
          "relations": [],
          "sentence_en": "The staging of CKD is based on the criteria of The Kidney Disease: Improving Global Outcomes (KDIGO)."
        }
      ],
      "paragraph_en": "1. Diagnostic criteria and staging of CKD: Diagnostic criteria for CKD: ① Kidney damage (abnormal kidney structure or function) ≥ 3 months, with or without decreased glomerular filtration rate (GFR), abnormal kidney pathology or kidney damage (abnormal blood, urine components or imaging examinations); ② GFR < 60ml·min-1·1.73m2)-1 for 3 months or more, with or without evidence of kidney damage. The staging of CKD refers to the criteria of The Kidney Disease: Improving Global Outcomes (KDIGO)."
    },
    {
      "paragraph_id": "11",
      "paragraph": "2.HUA的诊断标准和分型：HUA的诊断标准：嘌呤饮食状态下，非同日2次空腹血尿酸(serum uric acid，SUA)水平，男性>420μmol/L，女性>357μmol/L；没有出现痛风或痛风石时为无症状HUA。HUA的分型诊断，是根据患者低嘌呤饮食5d后，留取24h尿检测尿尿酸水平的结果，分为3型，具体如下：(1)尿酸排泄不良型：尿酸排泄<0.48mg·kg-1·h-1，尿酸清除率<6.2ml/min；⑵尿酸生成过多型：尿酸排泄>0.51mg·kg-1·h-1，尿酸清除率≥6.2ml/min；(3)混合型：尿酸排泄>0.51mg·kg-1·h-1，尿酸清除率<6.2ml/min。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.HUA的诊断标准和分型：HUA的诊断标准：嘌呤饮食状态下，非同日2次空腹血尿酸(serum uric acid，SUA)水平，男性>420μmol/L，女性>357μmol/L；没有出现痛风或痛风石时为无症状HUA。HUA的分型诊断，是根据患者低嘌呤饮食5d后，留取24h尿检测尿尿酸水平的结果，分为3型，具体如下：(1)尿酸排泄不良型：尿酸排泄<0.48mg·kg-1·h-1，尿酸清除率<6.2ml/min；⑵尿酸生成过多型：尿酸排泄>0.51mg·kg-1·h-1，尿酸清除率≥6.2ml/min；(3)混合型：尿酸排泄>0.51mg·kg-1·h-1，尿酸清除率<6.2ml/min。",
          "start_idx": 0,
          "end_idx": 298,
          "entities": [
            {
              "entity_id": "T46",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 5,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T47",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 14,
              "end_idx": 17,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T48",
              "entity": "男性>420μmol/L",
              "entity_type": "Test_Value",
              "start_idx": 65,
              "end_idx": 77,
              "entity_en": "Men > 420 μmol/L"
            },
            {
              "entity_id": "T49",
              "entity": "女性>357μmol/L",
              "entity_type": "Test_Value",
              "start_idx": 78,
              "end_idx": 90,
              "entity_en": "Women>357 μmol/L"
            },
            {
              "entity_id": "T50",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 95,
              "end_idx": 97,
              "entity_en": "gout"
            },
            {
              "entity_id": "T51",
              "entity": "痛风石",
              "entity_type": "Disease",
              "start_idx": 98,
              "end_idx": 101,
              "entity_en": "Tophi"
            },
            {
              "entity_id": "T52",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 106,
              "end_idx": 109,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T53",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 110,
              "end_idx": 113,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T54",
              "entity": "尿尿酸",
              "entity_type": "Test_items",
              "start_idx": 141,
              "end_idx": 144,
              "entity_en": "Urine uric acid"
            },
            {
              "entity_id": "T55",
              "entity": "尿酸排泄",
              "entity_type": "Test_items",
              "start_idx": 171,
              "end_idx": 175,
              "entity_en": "Uric acid excretion"
            },
            {
              "entity_id": "T56",
              "entity": "尿酸清除率",
              "entity_type": "Test_items",
              "start_idx": 192,
              "end_idx": 197,
              "entity_en": "Uric acid clearance"
            },
            {
              "entity_id": "T57",
              "entity": "尿酸排泄",
              "entity_type": "Test_items",
              "start_idx": 217,
              "end_idx": 221,
              "entity_en": "Uric acid excretion"
            },
            {
              "entity_id": "T58",
              "entity": "尿酸清除率",
              "entity_type": "Test_items",
              "start_idx": 238,
              "end_idx": 243,
              "entity_en": "Uric acid clearance"
            },
            {
              "entity_id": "T59",
              "entity": "尿酸排泄",
              "entity_type": "Test_items",
              "start_idx": 261,
              "end_idx": 265,
              "entity_en": "Uric acid excretion"
            },
            {
              "entity_id": "T60",
              "entity": "尿酸清除率",
              "entity_type": "Test_items",
              "start_idx": 282,
              "end_idx": 287,
              "entity_en": "Uric acid clearance"
            },
            {
              "entity_id": "T61",
              "entity": "<0.48mg·kg-1·h-1",
              "entity_type": "Test_Value",
              "start_idx": 175,
              "end_idx": 191,
              "entity_en": "<0.48mg·kg-1·h-1"
            },
            {
              "entity_id": "T62",
              "entity": "<6.2ml/min",
              "entity_type": "Test_Value",
              "start_idx": 197,
              "end_idx": 207,
              "entity_en": "<6.2ml/min"
            },
            {
              "entity_id": "T63",
              "entity": ">0.51mg·kg-1·h-1",
              "entity_type": "Test_Value",
              "start_idx": 221,
              "end_idx": 237,
              "entity_en": ">0.51mg·kg-1·h-1"
            },
            {
              "entity_id": "T64",
              "entity": "≥6.2ml/min",
              "entity_type": "Test_Value",
              "start_idx": 243,
              "end_idx": 253,
              "entity_en": "≥6.2ml/min"
            },
            {
              "entity_id": "T65",
              "entity": ">0.51mg·kg-1·h-1",
              "entity_type": "Test_Value",
              "start_idx": 265,
              "end_idx": 281,
              "entity_en": ">0.51mg·kg-1·h-1"
            },
            {
              "entity_id": "T66",
              "entity": "<6.2ml/min",
              "entity_type": "Test_Value",
              "start_idx": 287,
              "end_idx": 297,
              "entity_en": "<6.2ml/min"
            },
            {
              "entity_id": "T67",
              "entity": "空腹血尿酸(serum uric acid，SUA)",
              "entity_type": "Test_items",
              "start_idx": 36,
              "end_idx": 62,
              "entity_en": "Fasting serum uric acid (SUA)"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R15",
              "head_entity_id": "T67",
              "tail_entity_id": "T47"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R16",
              "head_entity_id": "T54",
              "tail_entity_id": "T53"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R17",
              "head_entity_id": "T55",
              "tail_entity_id": "T53"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R18",
              "head_entity_id": "T56",
              "tail_entity_id": "T53"
            }
          ],
          "sentence_en": "2. Diagnostic criteria and classification of HUA: Diagnostic criteria of HUA: fasting serum uric acid (SUA) levels of >420 μmol/L for males and >357 μmol/L for females on two different days under a purine diet; asymptomatic HUA occurs when there is no gout or tophi. The classification of HUA is based on the results of 24-hour urine test for uric acid levels after the patient has been on a low-purine diet for 5 days. It is divided into three types as follows: (1) poor uric acid excretion type: uric acid excretion <0.48 mg·kg-1·h-1, uric acid clearance rate <6.2 ml/min; (2) excessive uric acid production type: uric acid excretion >0.51 mg·kg-1·h-1, uric acid clearance rate ≥6.2 ml/min; (3) mixed type: uric acid excretion >0.51 mg·kg-1·h-1, uric acid clearance rate <6.2 ml/min."
        }
      ],
      "paragraph_en": "2. Diagnostic criteria and classification of HUA: Diagnostic criteria of HUA: fasting serum uric acid (SUA) levels of >420 μmol/L for males and >357 μmol/L for females on two different days under a purine diet; asymptomatic HUA occurs when there is no gout or tophi. The classification of HUA is based on the results of 24-hour urine test for uric acid levels after the patient has been on a low-purine diet for 5 days. It is divided into three types, as follows: (1) poor uric acid excretion type: uric acid excretion <0.48 mg·kg-1·h-1, uric acid clearance rate <6.2 ml/min; (2) excessive uric acid production type: uric acid excretion >0.51 mg·kg-1·h-1, uric acid clearance rate ≥6.2 ml/min; (3) mixed type: uric acid excretion >0.51 mg·kg-1·h-1, uric acid clearance rate <6.2 ml/min."
    },
    {
      "paragraph_id": "12",
      "paragraph": "治疗",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "治疗",
          "start_idx": 0,
          "end_idx": 2,
          "entities": [],
          "relations": [],
          "sentence_en": "treat"
        }
      ],
      "paragraph_en": "treat"
    },
    {
      "paragraph_id": "13",
      "paragraph": "一、患者教育和规律随访监测",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "一、患者教育和规律随访监测",
          "start_idx": 0,
          "end_idx": 13,
          "entities": [],
          "relations": [],
          "sentence_en": "1. Patient education and regular follow-up monitoring"
        }
      ],
      "paragraph_en": "1. Patient education and regular follow-up monitoring"
    },
    {
      "paragraph_id": "14",
      "paragraph": "积极开展患者教育，提高患者防病、治病的意识，提高治疗依从性，对于伴有HUA的CKD患者的治疗至关重要。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "积极开展患者教育，提高患者防病、治病的意识，提高治疗依从性，对于伴有HUA的CKD患者的治疗至关重要。",
          "start_idx": 0,
          "end_idx": 51,
          "entities": [
            {
              "entity_id": "T68",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 34,
              "end_idx": 37,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T69",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 38,
              "end_idx": 41,
              "entity_en": "CKD"
            }
          ],
          "relations": [],
          "sentence_en": "Actively carrying out patient education, raising patients' awareness of disease prevention and treatment, and improving treatment compliance are crucial for the treatment of CKD patients with HUA."
        }
      ],
      "paragraph_en": "Actively carrying out patient education, raising patients' awareness of disease prevention and treatment, and improving treatment compliance are crucial for the treatment of CKD patients with HUA."
    },
    {
      "paragraph_id": "15",
      "paragraph": "1.生活方式指导：对患者生活方式的指导应包括以下方面：健康饮食(详见表1)、坚持适度运动、限制体重和限制烟酒等。建议患者根据个人情况坚持适度运动(每天30min以上中等强度的锻炼，如散步、太极拳、瑜伽、阻力训练等有氧运动)。患者在运动中应避免剧烈运动及突然受凉。肥胖者应减体重，控制体重在正常范围。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.生活方式指导：对患者生活方式的指导应包括以下方面：健康饮食(详见表1)、坚持适度运动、限制体重和限制烟酒等。",
          "start_idx": 0,
          "end_idx": 56,
          "entities": [
            {
              "entity_id": "T70",
              "entity": "健康饮食",
              "entity_type": "Treatment",
              "start_idx": 27,
              "end_idx": 31,
              "entity_en": "Healthy eating"
            },
            {
              "entity_id": "T71",
              "entity": "坚持适度运动",
              "entity_type": "Treatment",
              "start_idx": 38,
              "end_idx": 44,
              "entity_en": "Keep exercising moderately"
            },
            {
              "entity_id": "T72",
              "entity": "限制体重",
              "entity_type": "Treatment",
              "start_idx": 45,
              "end_idx": 49,
              "entity_en": "Weight Limit"
            },
            {
              "entity_id": "T73",
              "entity": "限制烟酒",
              "entity_type": "Treatment",
              "start_idx": 50,
              "end_idx": 54,
              "entity_en": "Limit tobacco and alcohol"
            }
          ],
          "relations": [],
          "sentence_en": "1. Lifestyle guidance: Guidance on patients' lifestyle should include the following aspects: healthy diet (see Table 1 for details), moderate exercise, weight control, and restriction of smoking and drinking."
        },
        {
          "sentence_id": "1",
          "sentence": "建议患者根据个人情况坚持适度运动(每天30min以上中等强度的锻炼，如散步、太极拳、瑜伽、阻力训练等有氧运动)。",
          "start_idx": 56,
          "end_idx": 112,
          "entities": [
            {
              "entity_id": "T74",
              "entity": "坚持适度运动(每天30min以上中等强度的锻炼，如散步、太极拳、瑜伽、阻力训练等有氧运动)",
              "entity_type": "Treatment",
              "start_idx": 10,
              "end_idx": 55,
              "entity_en": "Adhere to moderate exercise (more than 30 minutes of moderate-intensity exercise every day, such as walking, Tai Chi, yoga, resistance training and other aerobic exercises)"
            }
          ],
          "relations": [],
          "sentence_en": "Patients are advised to adhere to moderate exercise according to their personal circumstances (moderate-intensity exercise for more than 30 minutes a day, such as walking, Tai Chi, yoga, resistance training and other aerobic exercises)."
        },
        {
          "sentence_id": "2",
          "sentence": "患者在运动中应避免剧烈运动及突然受凉。",
          "start_idx": 112,
          "end_idx": 131,
          "entities": [],
          "relations": [],
          "sentence_en": "Patients should avoid strenuous exercise and sudden cold during exercise."
        },
        {
          "sentence_id": "3",
          "sentence": "肥胖者应减体重，控制体重在正常范围。",
          "start_idx": 131,
          "end_idx": 149,
          "entities": [
            {
              "entity_id": "T75",
              "entity": "减体重",
              "entity_type": "Treatment",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "Weight loss"
            }
          ],
          "relations": [],
          "sentence_en": "Obese people should lose weight and keep their weight within the normal range."
        }
      ],
      "paragraph_en": "1. Lifestyle guidance: Guidance on the patient's lifestyle should include the following aspects: healthy diet (see Table 1 for details), moderate exercise, weight control, and restriction of tobacco and alcohol consumption. Patients are advised to exercise moderately according to their personal circumstances (more than 30 minutes of moderate intensity exercise per day, such as walking, Tai Chi, yoga, resistance training and other aerobic exercises). Patients should avoid strenuous exercise and sudden cold during exercise. Obese people should lose weight and keep their weight within the normal range."
    },
    {
      "paragraph_id": "16",
      "paragraph": "2.规律随访监测：对伴有HUA的CKD患者，建议治疗前全面评估肾功能和合并症、并发症情况，并在治疗过程中向患者强调规律随访监测的重要性。建议患者在监测估算肾小球滤过率(eGFR)、尿蛋白水平的同时，至少每3~6个月检测1次血尿酸水平。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.规律随访监测：对伴有HUA的CKD患者，建议治疗前全面评估肾功能和合并症、并发症情况，并在治疗过程中向患者强调规律随访监测的重要性。",
          "start_idx": 0,
          "end_idx": 68,
          "entities": [
            {
              "entity_id": "T76",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 15,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T77",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 16,
              "end_idx": 19,
              "entity_en": "CKD"
            }
          ],
          "relations": [],
          "sentence_en": "2. Regular follow-up monitoring: For CKD patients with HUA, it is recommended to comprehensively evaluate renal function and comorbidities and complications before treatment, and emphasize the importance of regular follow-up monitoring to patients during treatment."
        },
        {
          "sentence_id": "1",
          "sentence": "建议患者在监测估算肾小球滤过率(eGFR)、尿蛋白水平的同时，至少每3~6个月检测1次血尿酸水平。",
          "start_idx": 68,
          "end_idx": 117,
          "entities": [
            {
              "entity_id": "T78",
              "entity": "肾小球滤过率(eGFR)",
              "entity_type": "Test_items",
              "start_idx": 9,
              "end_idx": 21,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T79",
              "entity": "尿蛋白",
              "entity_type": "Test_items",
              "start_idx": 22,
              "end_idx": 25,
              "entity_en": "Urine protein"
            },
            {
              "entity_id": "T80",
              "entity": "血尿酸",
              "entity_type": "Test_items",
              "start_idx": 43,
              "end_idx": 46,
              "entity_en": "Serum uric acid"
            }
          ],
          "relations": [],
          "sentence_en": "It is recommended that patients test their blood uric acid levels at least once every 3 to 6 months while monitoring their estimated glomerular filtration rate (eGFR) and urine protein levels."
        }
      ],
      "paragraph_en": "2. Regular follow-up monitoring: For CKD patients with HUA, it is recommended to fully evaluate renal function and comorbidities and complications before treatment, and emphasize the importance of regular follow-up monitoring to patients during treatment. It is recommended that patients test their blood uric acid levels at least once every 3 to 6 months while monitoring the estimated glomerular filtration rate (eGFR) and urine protein levels."
    },
    {
      "paragraph_id": "17",
      "paragraph": "二、饮食治疗",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二、饮食治疗",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [
            {
              "entity_id": "T81",
              "entity": "饮食治疗",
              "entity_type": "Treatment",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Diet therapy"
            }
          ],
          "relations": [],
          "sentence_en": "2. Diet therapy"
        }
      ],
      "paragraph_en": "2. Diet therapy"
    },
    {
      "paragraph_id": "18",
      "paragraph": "1.健康饮食：饮食治疗在伴有HUA的CKD患者治疗中占有非常重要的地位，研究显示饮食治疗可以降低10%~18%的血尿酸水平或使血尿酸降低70~90μmol/L。推荐患者的饮食应以低嘌呤食物为主，具体建议详见表1。对于患者正在接受非透析治疗的CKD患者，应结合低蛋白饮食营养方案。避免高蛋白饮食、海鲜、动物内脏、大量乳制品的食用。避免啤酒、白酒，也应减少富含果糖的饮料摄入。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.健康饮食：饮食治疗在伴有HUA的CKD患者治疗中占有非常重要的地位，研究显示饮食治疗可以降低10%~18%的血尿酸水平或使血尿酸降低70~90μmol/L。推荐患者的饮食应以低嘌呤食物为主，具体建议详见表1。对于患者正在接受非透析治疗的CKD患者，应结合低蛋白饮食营养方案。",
          "start_idx": 0,
          "end_idx": 139,
          "entities": [
            {
              "entity_id": "T82",
              "entity": "健康饮食",
              "entity_type": "Treatment",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "Healthy eating"
            },
            {
              "entity_id": "T83",
              "entity": "饮食治疗",
              "entity_type": "Treatment",
              "start_idx": 7,
              "end_idx": 11,
              "entity_en": "Diet therapy"
            },
            {
              "entity_id": "T84",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 14,
              "end_idx": 17,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T85",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 18,
              "end_idx": 21,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T86",
              "entity": "饮食治疗",
              "entity_type": "Treatment",
              "start_idx": 40,
              "end_idx": 44,
              "entity_en": "Diet therapy"
            },
            {
              "entity_id": "T87",
              "entity": "血尿酸",
              "entity_type": "Test_items",
              "start_idx": 56,
              "end_idx": 59,
              "entity_en": "Serum uric acid"
            },
            {
              "entity_id": "T88",
              "entity": "血尿酸",
              "entity_type": "Test_items",
              "start_idx": 63,
              "end_idx": 66,
              "entity_en": "Serum uric acid"
            },
            {
              "entity_id": "T89",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 120,
              "end_idx": 123,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T90",
              "entity": "低蛋白饮食",
              "entity_type": "Treatment",
              "start_idx": 129,
              "end_idx": 134,
              "entity_en": "Low-protein diet"
            },
            {
              "entity_id": "T91",
              "entity": "降低70~90μmol/L",
              "entity_type": "Test_Value",
              "start_idx": 66,
              "end_idx": 79,
              "entity_en": "Reduce 70~90μmol/L"
            }
          ],
          "relations": [
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R19",
              "head_entity_id": "T82",
              "tail_entity_id": "T84"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R20",
              "head_entity_id": "T82",
              "tail_entity_id": "T85"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R21",
              "head_entity_id": "T83",
              "tail_entity_id": "T84"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R22",
              "head_entity_id": "T83",
              "tail_entity_id": "T85"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R23",
              "head_entity_id": "T86",
              "tail_entity_id": "T84"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R24",
              "head_entity_id": "T87",
              "tail_entity_id": "T84"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R25",
              "head_entity_id": "T88",
              "tail_entity_id": "T84"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R26",
              "head_entity_id": "T86",
              "tail_entity_id": "T85"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R27",
              "head_entity_id": "T87",
              "tail_entity_id": "T85"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R28",
              "head_entity_id": "T88",
              "tail_entity_id": "T85"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R29",
              "head_entity_id": "T90",
              "tail_entity_id": "T89"
            }
          ],
          "sentence_en": "1. Healthy diet: Diet therapy plays a very important role in the treatment of CKD patients with HUA. Studies have shown that dietary therapy can reduce blood uric acid levels by 10% to 18% or reduce blood uric acid by 70 to 90 μmol/L. It is recommended that patients should eat a diet based on low-purine foods. For specific recommendations, see Table 1. For CKD patients who are receiving non-dialysis treatment, a low-protein diet nutrition plan should be combined."
        },
        {
          "sentence_id": "1",
          "sentence": "避免高蛋白饮食、海鲜、动物内脏、大量乳制品的食用。",
          "start_idx": 139,
          "end_idx": 164,
          "entities": [
            {
              "entity_id": "T92",
              "entity": "避免高蛋白饮食、海鲜、动物内脏、大量乳制品的食用",
              "entity_type": "Treatment",
              "start_idx": 0,
              "end_idx": 24,
              "entity_en": "Avoid high-protein diets, seafood, animal offal, and large amounts of dairy products"
            }
          ],
          "relations": [],
          "sentence_en": "Avoid high-protein diets, seafood, animal offal, and large amounts of dairy products."
        },
        {
          "sentence_id": "2",
          "sentence": "避免啤酒、白酒，也应减少富含果糖的饮料摄入。",
          "start_idx": 164,
          "end_idx": 186,
          "entities": [
            {
              "entity_id": "T93",
              "entity": "避免啤酒、白酒，也应减少富含果糖的饮料摄入",
              "entity_type": "Treatment",
              "start_idx": 0,
              "end_idx": 21,
              "entity_en": "Avoid beer and liquor, and reduce the intake of fructose-rich beverages"
            }
          ],
          "relations": [],
          "sentence_en": "Avoid beer and liquor, and reduce the intake of fructose-rich beverages."
        }
      ],
      "paragraph_en": "1. Healthy diet: Diet therapy plays a very important role in the treatment of CKD patients with HUA. Studies have shown that dietary therapy can reduce blood uric acid levels by 10% to 18% or reduce blood uric acid by 70 to 90 μmol/L. It is recommended that patients should eat a diet based on low-purine foods. For specific recommendations, see Table 1. For CKD patients who are receiving non-dialysis treatment, a low-protein diet nutrition plan should be combined. Avoid high-protein diets, seafood, animal offal, and large amounts of dairy products. Avoid beer and liquor, and reduce the intake of fructose-rich beverages."
    },
    {
      "paragraph_id": "19",
      "paragraph": "2.多饮水：建议患者每日饮水量2000ml以上，可促进尿酸排泄并预防尿路结石。结合患者肾功能及血压情况，从患者尿量的角度，建议保证每日的尿量在1500ml以上，最好2000ml。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.多饮水：建议患者每日饮水量2000ml以上，可促进尿酸排泄并预防尿路结石。",
          "start_idx": 0,
          "end_idx": 39,
          "entities": [
            {
              "entity_id": "T94",
              "entity": "多饮水",
              "entity_type": "Treatment",
              "start_idx": 2,
              "end_idx": 5,
              "entity_en": "Drink plenty of water"
            },
            {
              "entity_id": "T95",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 27,
              "end_idx": 29,
              "entity_en": "Uric acid"
            },
            {
              "entity_id": "T96",
              "entity": "尿路结石",
              "entity_type": "Disease",
              "start_idx": 34,
              "end_idx": 38,
              "entity_en": "Urinary tract stones"
            }
          ],
          "relations": [
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R30",
              "head_entity_id": "T94",
              "tail_entity_id": "T96"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R31",
              "head_entity_id": "T95",
              "tail_entity_id": "T96"
            }
          ],
          "sentence_en": "2. Drink more water: It is recommended that patients drink more than 2000 ml of water per day, which can promote uric acid excretion and prevent urinary stones."
        },
        {
          "sentence_id": "1",
          "sentence": "结合患者肾功能及血压情况，从患者尿量的角度，建议保证每日的尿量在1500ml以上，最好2000ml。",
          "start_idx": 39,
          "end_idx": 89,
          "entities": [],
          "relations": [],
          "sentence_en": "Taking into account the patient's renal function and blood pressure, and from the perspective of the patient's urine volume, it is recommended to ensure that the daily urine volume is above 1500ml, preferably 2000ml."
        }
      ],
      "paragraph_en": "2. Drink more water: It is recommended that patients drink more than 2000 ml of water per day, which can promote uric acid excretion and prevent urinary stones. Combined with the patient's renal function and blood pressure, from the perspective of the patient's urine volume, it is recommended to ensure that the daily urine volume is more than 1500 ml, preferably 2000 ml."
    },
    {
      "paragraph_id": "20",
      "paragraph": "3.适当碱化尿液：建议碱化尿液，尿pH在6.2~6.9范围间内最有利于尿酸盐结晶溶解和从尿液排出，但尿pH>7.0易形成草酸钙及其他类结石。因此，碱化尿液过程中要注意检测患者的尿pH值。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.适当碱化尿液：建议碱化尿液，尿pH在6.2~6.9范围间内最有利于尿酸盐结晶溶解和从尿液排出，但尿pH>7.0易形成草酸钙及其他类结石。",
          "start_idx": 0,
          "end_idx": 70,
          "entities": [
            {
              "entity_id": "T97",
              "entity": "尿pH",
              "entity_type": "Test_items",
              "start_idx": 16,
              "end_idx": 19,
              "entity_en": "Urine pH"
            },
            {
              "entity_id": "T98",
              "entity": "尿pH",
              "entity_type": "Test_items",
              "start_idx": 50,
              "end_idx": 53,
              "entity_en": "Urine pH"
            },
            {
              "entity_id": "T99",
              "entity": ">7.0",
              "entity_type": "Test_Value",
              "start_idx": 53,
              "end_idx": 57,
              "entity_en": ">7.0"
            },
            {
              "entity_id": "T101",
              "entity": "6.2~6.9",
              "entity_type": "Test_Value",
              "start_idx": 20,
              "end_idx": 27,
              "entity_en": "6.2~6.9"
            }
          ],
          "relations": [],
          "sentence_en": "3. Appropriate alkalization of urine: It is recommended to alkalize urine. Urine pH in the range of 6.2~6.9 is most conducive to the dissolution of urate crystals and excretion from urine, but urine pH>7.0 is prone to the formation of calcium oxalate and other types of stones."
        },
        {
          "sentence_id": "1",
          "sentence": "因此，碱化尿液过程中要注意检测患者的尿pH值。",
          "start_idx": 70,
          "end_idx": 93,
          "entities": [
            {
              "entity_id": "T100",
              "entity": "尿pH值",
              "entity_type": "Test_items",
              "start_idx": 18,
              "end_idx": 22,
              "entity_en": "Urine pH"
            }
          ],
          "relations": [],
          "sentence_en": "Therefore, during the process of alkalinizing urine, it is important to pay attention to monitoring the patient's urine pH value."
        }
      ],
      "paragraph_en": "3. Appropriately alkalize urine: It is recommended to alkalize urine. Urine pH between 6.2 and 6.9 is most conducive to the dissolution of urate crystals and excretion from urine, but urine pH>7.0 is prone to the formation of calcium oxalate and other types of stones. Therefore, during the process of alkalizing urine, it is necessary to pay attention to the detection of the patient's urine pH value."
    },
    {
      "paragraph_id": "21",
      "paragraph": "建议碱化尿液的方法：碳酸氢钠或枸橼酸合剂。碳酸氢钠(小苏打)口服：每次0.5~1g，每日3次。在CKD患者中碳酸氢钠可同时改善代谢性酸中毒，因此具有双重功效。但也需要注意钠负荷诱发患者充血性心力衰竭和水肿的可能。枸橼酸合剂口服时应注意监测CKD患者的血钾水平，避免发生高钾血症。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "建议碱化尿液的方法：碳酸氢钠或枸橼酸合剂。",
          "start_idx": 0,
          "end_idx": 21,
          "entities": [
            {
              "entity_id": "T102",
              "entity": "枸橼酸合剂",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 20,
              "entity_en": "Citric acid mixture"
            },
            {
              "entity_id": "T103",
              "entity": "碳酸氢钠",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 14,
              "entity_en": "Sodium bicarbonate"
            }
          ],
          "relations": [],
          "sentence_en": "Recommended methods for alkalinizing urine: sodium bicarbonate or citric acid mixture."
        },
        {
          "sentence_id": "1",
          "sentence": "碳酸氢钠(小苏打)口服：每次0.5~1g，每日3次。在CKD患者中碳酸氢钠可同时改善代谢性酸中毒，因此具有双重功效。但也需要注意钠负荷诱发患者充血性心力衰竭和水肿的可能。枸橼酸合剂口服时应注意监测CKD患者的血钾水平，避免发生高钾血症。",
          "start_idx": 21,
          "end_idx": 139,
          "entities": [
            {
              "entity_id": "T104",
              "entity": "碳酸氢钠(小苏打)",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 9,
              "entity_en": "Sodium bicarbonate (baking soda)"
            },
            {
              "entity_id": "T105",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 9,
              "end_idx": 11,
              "entity_en": "oral"
            },
            {
              "entity_id": "T106",
              "entity": "每次0.5~1g",
              "entity_type": "Amount",
              "start_idx": 12,
              "end_idx": 20,
              "entity_en": "0.5~1g each time"
            },
            {
              "entity_id": "T107",
              "entity": "每日3次",
              "entity_type": "Frequency",
              "start_idx": 21,
              "end_idx": 25,
              "entity_en": "3 times a day"
            },
            {
              "entity_id": "T108",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 27,
              "end_idx": 30,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T109",
              "entity": "碳酸氢钠",
              "entity_type": "Drug",
              "start_idx": 33,
              "end_idx": 37,
              "entity_en": "Sodium bicarbonate"
            },
            {
              "entity_id": "T110",
              "entity": "充血性心力衰竭",
              "entity_type": "Disease",
              "start_idx": 71,
              "end_idx": 78,
              "entity_en": "Congestive heart failure"
            },
            {
              "entity_id": "T111",
              "entity": "水肿",
              "entity_type": "Disease",
              "start_idx": 79,
              "end_idx": 81,
              "entity_en": "Edema"
            },
            {
              "entity_id": "T112",
              "entity": "枸橼酸合剂",
              "entity_type": "Drug",
              "start_idx": 85,
              "end_idx": 90,
              "entity_en": "Citric acid mixture"
            },
            {
              "entity_id": "T113",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 90,
              "end_idx": 92,
              "entity_en": "oral"
            },
            {
              "entity_id": "T114",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 98,
              "end_idx": 101,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T115",
              "entity": "血钾",
              "entity_type": "Test_items",
              "start_idx": 104,
              "end_idx": 106,
              "entity_en": "Serum potassium"
            },
            {
              "entity_id": "T116",
              "entity": "高钾血症",
              "entity_type": "ADE",
              "start_idx": 113,
              "end_idx": 117,
              "entity_en": "Hyperkalemia"
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R32",
              "head_entity_id": "T105",
              "tail_entity_id": "T104"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R33",
              "head_entity_id": "T106",
              "tail_entity_id": "T104"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R34",
              "head_entity_id": "T107",
              "tail_entity_id": "T104"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R35",
              "head_entity_id": "T109",
              "tail_entity_id": "T108"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R36",
              "head_entity_id": "T113",
              "tail_entity_id": "T112"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R37",
              "head_entity_id": "T116",
              "tail_entity_id": "T112"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R38",
              "head_entity_id": "T115",
              "tail_entity_id": "T114"
            }
          ],
          "sentence_en": "Sodium bicarbonate (baking soda) oral administration: 0.5-1g each time, 3 times a day. Sodium bicarbonate can also improve metabolic acidosis in CKD patients, so it has a dual effect. However, it is also necessary to pay attention to the possibility that sodium load may induce congestive heart failure and edema in patients. When taking citric acid mixture orally, the blood potassium level of CKD patients should be monitored to avoid hyperkalemia."
        }
      ],
      "paragraph_en": "Recommended methods for alkalinizing urine: sodium bicarbonate or citric acid mixture. Sodium bicarbonate (baking soda) oral administration: 0.5-1g each time, 3 times a day. Sodium bicarbonate can also improve metabolic acidosis in CKD patients, so it has a dual effect. However, it is also necessary to pay attention to the possibility that sodium load may induce congestive heart failure and edema in patients. When taking citric acid mixture orally, the blood potassium level of CKD patients should be monitored to avoid hyperkalemia."
    },
    {
      "paragraph_id": "22",
      "paragraph": "三、药物治疗",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "三、药物治疗",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [],
          "relations": [],
          "sentence_en": "3. Drug treatment"
        }
      ],
      "paragraph_en": "3. Drug treatment"
    },
    {
      "paragraph_id": "23",
      "paragraph": "(一)急性痛风发作治疗",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(一)急性痛风发作治疗",
          "start_idx": 0,
          "end_idx": 11,
          "entities": [
            {
              "entity_id": "T117",
              "entity": "急性痛风",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 7,
              "entity_en": "Acute gout"
            }
          ],
          "relations": [],
          "sentence_en": "(I) Treatment of acute gout attacks"
        }
      ],
      "paragraph_en": "(I) Treatment of acute gout attacks"
    },
    {
      "paragraph_id": "24",
      "paragraph": "痛风关节炎急性发作期的治疗建议：及早(应在24h内)给予抗炎止痛治疗，推荐的用药包括：非甾体抗炎药(NSAIDs)、糖皮质激素和秋水仙碱。建议使用选择性环氧化酶2(COX-2)抑制剂，该药可针对性地抑制COX-2，减少对CKD患者胃肠道损伤的不良作用。研究显示，依托考昔治疗急性痛风疗效优于吲哚美辛、双氯芬酸、塞来昔布。但CKD患者在使用NSAIDs时应警惕引起急性肾损伤，更应充分水化，密切注意肾功能情况。NSAIDs不耐受或禁忌的患者可考虑用糖皮质激素(如泼尼松30~35mg/d，共3~5d)或秋水仙碱。秋水仙碱最好在症状出现的12~24h内开始使用，但其不能用于重度肾功能或肝功能损害的患者。急性期不宜积极降尿酸治疗，除非一直在服用降尿酸药物。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "痛风关节炎急性发作期的治疗建议：及早(应在24h内)给予抗炎止痛治疗，推荐的用药包括：非甾体抗炎药(NSAIDs)、糖皮质激素和秋水仙碱。建议使用选择性环氧化酶2(COX-2)抑制剂，该药可针对性地抑制COX-2，减少对CKD患者胃肠道损伤的不良作用。研究显示，依托考昔治疗急性痛风疗效优于吲哚美辛、双氯芬酸、塞来昔布。但CKD患者在使用NSAIDs时应警惕引起急性肾损伤，更应充分水化，密切注意肾功能情况。NSAIDs不耐受或禁忌的患者可考虑用糖皮质激素(如泼尼松30~35mg/d，共3~5d)或秋水仙碱。秋水仙碱最好在症状出现的12~24h内开始使用，但其不能用于重度肾功能或肝功能损害的患者。",
          "start_idx": 0,
          "end_idx": 300,
          "entities": [
            {
              "entity_id": "T118",
              "entity": "痛风关节炎",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 5,
              "entity_en": "Gouty arthritis"
            },
            {
              "entity_id": "T119",
              "entity": "非甾体抗炎药(NSAIDs)",
              "entity_type": "Drug",
              "start_idx": 43,
              "end_idx": 57,
              "entity_en": "Nonsteroidal anti-inflammatory drugs (NSAIDs)"
            },
            {
              "entity_id": "T120",
              "entity": "糖皮质激素",
              "entity_type": "Drug",
              "start_idx": 58,
              "end_idx": 63,
              "entity_en": "Glucocorticoids"
            },
            {
              "entity_id": "T121",
              "entity": "秋水仙碱",
              "entity_type": "Drug",
              "start_idx": 64,
              "end_idx": 68,
              "entity_en": "Colchicine"
            },
            {
              "entity_id": "T122",
              "entity": "选择性环氧化酶2(COX-2)抑制剂",
              "entity_type": "Drug",
              "start_idx": 73,
              "end_idx": 91,
              "entity_en": "Selective cyclooxygenase 2 (COX-2) inhibitors"
            },
            {
              "entity_id": "T123",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 110,
              "end_idx": 113,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T124",
              "entity": "依托考昔",
              "entity_type": "Drug",
              "start_idx": 131,
              "end_idx": 135,
              "entity_en": "Etoricoxib"
            },
            {
              "entity_id": "T125",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 139,
              "end_idx": 141,
              "entity_en": "gout"
            },
            {
              "entity_id": "T126",
              "entity": "吲哚美辛",
              "entity_type": "Drug",
              "start_idx": 145,
              "end_idx": 149,
              "entity_en": "Indomethacin"
            },
            {
              "entity_id": "T127",
              "entity": "双氯芬酸",
              "entity_type": "Drug",
              "start_idx": 150,
              "end_idx": 154,
              "entity_en": "Diclofenac"
            },
            {
              "entity_id": "T128",
              "entity": "塞来昔布",
              "entity_type": "Drug",
              "start_idx": 155,
              "end_idx": 159,
              "entity_en": "Celecoxib"
            },
            {
              "entity_id": "T129",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 161,
              "end_idx": 164,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T130",
              "entity": "NSAIDs",
              "entity_type": "Drug",
              "start_idx": 169,
              "end_idx": 175,
              "entity_en": "NSAIDs"
            },
            {
              "entity_id": "T131",
              "entity": "急性肾损伤",
              "entity_type": "ADE",
              "start_idx": 181,
              "end_idx": 186,
              "entity_en": "Acute kidney injury"
            },
            {
              "entity_id": "T132",
              "entity": "NSAIDs",
              "entity_type": "Drug",
              "start_idx": 204,
              "end_idx": 210,
              "entity_en": "NSAIDs"
            },
            {
              "entity_id": "T133",
              "entity": "糖皮质激素",
              "entity_type": "Drug",
              "start_idx": 223,
              "end_idx": 228,
              "entity_en": "Glucocorticoids"
            },
            {
              "entity_id": "T134",
              "entity": "泼尼松",
              "entity_type": "Drug",
              "start_idx": 230,
              "end_idx": 233,
              "entity_en": "Prednisone"
            },
            {
              "entity_id": "T135",
              "entity": "秋水仙碱",
              "entity_type": "Drug",
              "start_idx": 250,
              "end_idx": 254,
              "entity_en": "Colchicine"
            },
            {
              "entity_id": "T136",
              "entity": "30~35mg/d",
              "entity_type": "Amount",
              "start_idx": 233,
              "end_idx": 242,
              "entity_en": "30–35 mg/day"
            },
            {
              "entity_id": "T137",
              "entity": "共3~5d",
              "entity_type": "Duration",
              "start_idx": 243,
              "end_idx": 248,
              "entity_en": "3~5 days in total"
            },
            {
              "entity_id": "T138",
              "entity": "秋水仙碱",
              "entity_type": "Drug",
              "start_idx": 255,
              "end_idx": 259,
              "entity_en": "Colchicine"
            },
            {
              "entity_id": "T141",
              "entity": "胃肠道损伤",
              "entity_type": "ADE",
              "start_idx": 115,
              "end_idx": 120,
              "entity_en": "Gastrointestinal damage"
            },
            {
              "entity_id": "T142",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 285,
              "end_idx": 287,
              "entity_en": "Severe"
            },
            {
              "entity_id": "T143",
              "entity": "肾功能或肝功能损害",
              "entity_type": "Disease",
              "start_idx": 287,
              "end_idx": 296,
              "entity_en": "Renal or hepatic impairment"
            },
            {
              "entity_id": "T144",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 287,
              "end_idx": 288,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T145",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 291,
              "end_idx": 292,
              "entity_en": "liver"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R39",
              "head_entity_id": "T119",
              "tail_entity_id": "T118"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R40",
              "head_entity_id": "T120",
              "tail_entity_id": "T118"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R41",
              "head_entity_id": "T121",
              "tail_entity_id": "T118"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R42",
              "head_entity_id": "T122",
              "tail_entity_id": "T123"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R43",
              "head_entity_id": "T124",
              "tail_entity_id": "T125"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R44",
              "head_entity_id": "T126",
              "tail_entity_id": "T125"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R45",
              "head_entity_id": "T127",
              "tail_entity_id": "T125"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R46",
              "head_entity_id": "T128",
              "tail_entity_id": "T125"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R47",
              "head_entity_id": "T130",
              "tail_entity_id": "T129"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R48",
              "head_entity_id": "T131",
              "tail_entity_id": "T130"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R49",
              "head_entity_id": "T137",
              "tail_entity_id": "T134"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R50",
              "head_entity_id": "T136",
              "tail_entity_id": "T134"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R51",
              "head_entity_id": "T144",
              "tail_entity_id": "T143"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R52",
              "head_entity_id": "T145",
              "tail_entity_id": "T143"
            }
          ],
          "sentence_en": "Treatment recommendations for acute attacks of gouty arthritis: Anti-inflammatory and analgesic treatment should be given as soon as possible (within 24 hours). Recommended medications include: nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, and colchicine. It is recommended to use selective cyclooxygenase 2 (COX-2) inhibitors, which can specifically inhibit COX-2 and reduce the adverse effects of gastrointestinal damage in patients with CKD. Studies have shown that etoricoxib is more effective than indomethacin, diclofenac, and celecoxib in the treatment of acute gout. However, CKD patients should be alert to the occurrence of acute kidney injury when using NSAIDs, and should be fully hydrated and pay close attention to renal function. Patients who are intolerant or contraindicated to NSAIDs may consider using glucocorticoids (such as prednisone 30~35mg/d, a total of 3~5d) or colchicine. Colchicine is best started within 12~24h of symptom onset, but it cannot be used in patients with severe renal or liver damage."
        },
        {
          "sentence_id": "1",
          "sentence": "急性期不宜积极降尿酸治疗，除非一直在服用降尿酸药物。",
          "start_idx": 300,
          "end_idx": 326,
          "entities": [
            {
              "entity_id": "T139",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 8,
              "end_idx": 10,
              "entity_en": "Uric acid"
            },
            {
              "entity_id": "T140",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 21,
              "end_idx": 23,
              "entity_en": "Uric acid"
            }
          ],
          "relations": [],
          "sentence_en": "Active uric acid-lowering treatment is not recommended during the acute phase unless you have been taking uric acid-lowering drugs."
        }
      ],
      "paragraph_en": "Treatment recommendations for acute attacks of gouty arthritis: Anti-inflammatory and analgesic treatment should be given as soon as possible (within 24 hours). Recommended medications include: nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, and colchicine. It is recommended to use selective cyclooxygenase 2 (COX-2) inhibitors, which can specifically inhibit COX-2 and reduce the adverse effects of gastrointestinal damage in patients with CKD. Studies have shown that etoricoxib is more effective than indomethacin, diclofenac, and celecoxib in the treatment of acute gout. However, CKD patients should be alert to the occurrence of acute kidney injury when using NSAIDs, and should be fully hydrated and pay close attention to renal function. Patients who are intolerant or contraindicated to NSAIDs may consider using glucocorticoids (such as prednisone 30-35 mg/d for 3-5 days) or colchicine. Colchicine is best started within 12-24 hours of symptom onset, but it cannot be used in patients with severe renal or liver damage. Active uric acid-lowering treatment is not recommended in the acute phase unless uric acid-lowering drugs have been taken."
    },
    {
      "paragraph_id": "25",
      "paragraph": "CKD患者痛风急性发作时应特别重视水化和碱化尿液，并在上述治疗的同时辅以局部NSAIDs药物的使用，改善患者的症状，最大限度减少全身用药的毒副作用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "CKD患者痛风急性发作时应特别重视水化和碱化尿液，并在上述治疗的同时辅以局部NSAIDs药物的使用，改善患者的症状，最大限度减少全身用药的毒副作用。",
          "start_idx": 0,
          "end_idx": 74,
          "entities": [
            {
              "entity_id": "T146",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T147",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 7,
              "entity_en": "gout"
            },
            {
              "entity_id": "T148",
              "entity": "NSAIDs药物",
              "entity_type": "Drug",
              "start_idx": 38,
              "end_idx": 46,
              "entity_en": "NSAIDs"
            },
            {
              "entity_id": "T149",
              "entity": "水化和碱化尿液",
              "entity_type": "Symptom",
              "start_idx": 17,
              "end_idx": 24,
              "entity_en": "Hydration and alkalinization of urine"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R53",
              "head_entity_id": "T148",
              "tail_entity_id": "T146"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R54",
              "head_entity_id": "T148",
              "tail_entity_id": "T147"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R55",
              "head_entity_id": "T149",
              "tail_entity_id": "T147"
            }
          ],
          "sentence_en": "When CKD patients have an acute attack of gout, they should pay special attention to hydration and alkalinization of urine, and use local NSAIDs in addition to the above treatments to improve the patient's symptoms and minimize the toxic side effects of systemic medications."
        }
      ],
      "paragraph_en": "When CKD patients have an acute attack of gout, they should pay special attention to hydration and alkalinization of urine, and use local NSAIDs in addition to the above treatments to improve the patient's symptoms and minimize the toxic side effects of systemic medications."
    },
    {
      "paragraph_id": "26",
      "paragraph": "(二)降尿酸治疗",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(二)降尿酸治疗",
          "start_idx": 0,
          "end_idx": 8,
          "entities": [
            {
              "entity_id": "T150",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 4,
              "end_idx": 6,
              "entity_en": "Uric acid"
            }
          ],
          "relations": [],
          "sentence_en": "(II) Uric acid lowering treatment"
        }
      ],
      "paragraph_en": "(II) Uric acid lowering therapy"
    },
    {
      "paragraph_id": "28",
      "paragraph": "1.抑制尿酸生成药物：",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.抑制尿酸生成药物：",
          "start_idx": 0,
          "end_idx": 11,
          "entities": [],
          "relations": [],
          "sentence_en": "1. Drugs that inhibit uric acid production:"
        }
      ],
      "paragraph_en": "1. Drugs that inhibit uric acid production:"
    },
    {
      "paragraph_id": "29",
      "paragraph": "(1)别嘌醇：适应证：①慢性原发性或继发性痛风的治疗；②伴或不伴痛风症状的高尿酸血症的CKD患者；③反复发作性尿酸结石患者；④预防白血病、淋巴瘤或其他肿瘤在化疗或放疗后继发的组织内尿酸盐沉积、肾结石等。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)别嘌醇：适应证：①慢性原发性或继发性痛风的治疗；②伴或不伴痛风症状的高尿酸血症的CKD患者；③反复发作性尿酸结石患者；④预防白血病、淋巴瘤或其他肿瘤在化疗或放疗后继发的组织内尿酸盐沉积、肾结石等。",
          "start_idx": 0,
          "end_idx": 101,
          "entities": [
            {
              "entity_id": "T151",
              "entity": "别嘌醇",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 6,
              "entity_en": "Allopurinol"
            },
            {
              "entity_id": "T152",
              "entity": "继发性痛风",
              "entity_type": "Disease",
              "start_idx": 18,
              "end_idx": 23,
              "entity_en": "Secondary gout"
            },
            {
              "entity_id": "T153",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 34,
              "entity_en": "gout"
            },
            {
              "entity_id": "T154",
              "entity": "高尿酸血症",
              "entity_type": "Disease",
              "start_idx": 37,
              "end_idx": 42,
              "entity_en": "Hyperuricemia"
            },
            {
              "entity_id": "T155",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 43,
              "end_idx": 46,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T156",
              "entity": "尿酸结石",
              "entity_type": "Disease",
              "start_idx": 55,
              "end_idx": 59,
              "entity_en": "Uric acid stones"
            },
            {
              "entity_id": "T157",
              "entity": "白血病",
              "entity_type": "Disease",
              "start_idx": 65,
              "end_idx": 68,
              "entity_en": "leukemia"
            },
            {
              "entity_id": "T158",
              "entity": "淋巴瘤",
              "entity_type": "Disease",
              "start_idx": 69,
              "end_idx": 72,
              "entity_en": "Lymphoma"
            },
            {
              "entity_id": "T159",
              "entity": "肿瘤",
              "entity_type": "Disease",
              "start_idx": 75,
              "end_idx": 77,
              "entity_en": "Tumor"
            },
            {
              "entity_id": "T160",
              "entity": "肾结石",
              "entity_type": "Disease",
              "start_idx": 96,
              "end_idx": 99,
              "entity_en": "Kidney stones"
            },
            {
              "entity_id": "T161",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 96,
              "end_idx": 97,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T162",
              "entity": "化疗",
              "entity_type": "Treatment",
              "start_idx": 78,
              "end_idx": 80,
              "entity_en": "Chemotherapy"
            },
            {
              "entity_id": "T163",
              "entity": "放疗",
              "entity_type": "Treatment",
              "start_idx": 81,
              "end_idx": 83,
              "entity_en": "Radiation therapy"
            },
            {
              "entity_id": "T164",
              "entity": "尿酸盐沉积",
              "entity_type": "Disease",
              "start_idx": 90,
              "end_idx": 95,
              "entity_en": "Urate deposition"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R56",
              "head_entity_id": "T151",
              "tail_entity_id": "T152"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R57",
              "head_entity_id": "T162",
              "tail_entity_id": "T159"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R58",
              "head_entity_id": "T163",
              "tail_entity_id": "T159"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R59",
              "head_entity_id": "T161",
              "tail_entity_id": "T160"
            }
          ],
          "sentence_en": "(1) Allopurinol: Indications: ① Treatment of chronic primary or secondary gout; ② CKD patients with hyperuricemia with or without gout symptoms; ③ Patients with recurrent uric acid stones; ④ Prevention of urate deposition in tissues and kidney stones secondary to chemotherapy or radiotherapy for leukemia, lymphoma or other tumors."
        }
      ],
      "paragraph_en": "(1) Allopurinol: Indications: ① Treatment of chronic primary or secondary gout; ② CKD patients with hyperuricemia with or without gout symptoms; ③ Patients with recurrent uric acid stones; ④ Prevention of urate deposition in tissues and kidney stones secondary to chemotherapy or radiotherapy for leukemia, lymphoma or other tumors."
    },
    {
      "paragraph_id": "30",
      "paragraph": "用法及用量：从小剂量起始，逐渐加量。初始剂量：每次50~100mg，每日1~3次。2~3周后增至每日300mg，分2~3次服用。肾功能下降时，如eGFR<60ml/min时别嘌醇应减量，推荐剂量为50~100mg/d，eGFR<15ml/min时应禁用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "用法及用量：从小剂量起始，逐渐加量。",
          "start_idx": 0,
          "end_idx": 18,
          "entities": [],
          "relations": [],
          "sentence_en": "Usage and dosage: Start with a small dose and gradually increase the dose."
        },
        {
          "sentence_id": "1",
          "sentence": "初始剂量：每次50~100mg，每日1~3次。2~3周后增至每日300mg，分2~3次服用。肾功能下降时，如eGFR<60ml/min时别嘌醇应减量，推荐剂量为50~100mg/d，eGFR<15ml/min时应禁用。",
          "start_idx": 18,
          "end_idx": 127,
          "entities": [
            {
              "entity_id": "T165",
              "entity": "每次50~100mg",
              "entity_type": "Amount",
              "start_idx": 5,
              "end_idx": 15,
              "entity_en": "50-100 mg each time"
            },
            {
              "entity_id": "T166",
              "entity": "每日300mg",
              "entity_type": "Amount",
              "start_idx": 30,
              "end_idx": 37,
              "entity_en": "300 mg daily"
            },
            {
              "entity_id": "T167",
              "entity": "分2~3次",
              "entity_type": "Frequency",
              "start_idx": 38,
              "end_idx": 43,
              "entity_en": "2~3 times"
            },
            {
              "entity_id": "T168",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 54,
              "end_idx": 58,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T169",
              "entity": "<60ml/min",
              "entity_type": "Test_Value",
              "start_idx": 58,
              "end_idx": 67,
              "entity_en": "<60ml/min"
            },
            {
              "entity_id": "T170",
              "entity": "别嘌醇",
              "entity_type": "Drug",
              "start_idx": 68,
              "end_idx": 71,
              "entity_en": "Allopurinol"
            },
            {
              "entity_id": "T171",
              "entity": "50~100mg/d",
              "entity_type": "Amount",
              "start_idx": 80,
              "end_idx": 90,
              "entity_en": "50–100 mg/day"
            },
            {
              "entity_id": "T172",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 91,
              "end_idx": 95,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T173",
              "entity": "<15ml/min",
              "entity_type": "Test_Value",
              "start_idx": 95,
              "end_idx": 104,
              "entity_en": "<15ml/min"
            },
            {
              "entity_id": "T174",
              "entity": "每日1~3次",
              "entity_type": "Frequency",
              "start_idx": 16,
              "end_idx": 22,
              "entity_en": "1 to 3 times a day"
            }
          ],
          "relations": [
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R60",
              "head_entity_id": "T171",
              "tail_entity_id": "T170"
            }
          ],
          "sentence_en": "Initial dose: 50~100 mg each time, 1~3 times a day. After 2~3 weeks, increase to 300 mg per day, taken in 2~3 times. When renal function declines, such as when eGFR<60ml/min, allopurinol should be reduced. The recommended dose is 50~100 mg/d. It should be disabled when eGFR<15ml/min."
        }
      ],
      "paragraph_en": "Usage and Dosage: Start with a small dose and gradually increase the dose. Initial dose: 50~100 mg each time, 1~3 times a day. After 2~3 weeks, increase to 300 mg per day, taken in 2~3 times. When renal function declines, such as when eGFR<60ml/min, allopurinol should be reduced. The recommended dose is 50~100mg/d. It should be disabled when eGFR<15ml/min."
    },
    {
      "paragraph_id": "31",
      "paragraph": "注意事项：①别嘌醇的严重不良反应与所用剂量相关，当使用最小有效剂量能够使血尿酸达标时，尽量不增加剂量。②控制急性痛风发作时，建议同时应用秋水仙碱或其他消炎药，尤其是在治疗的早期。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "注意事项：①别嘌醇的严重不良反应与所用剂量相关，当使用最小有效剂量能够使血尿酸达标时，尽量不增加剂量。②控制急性痛风发作时，建议同时应用秋水仙碱或其他消炎药，尤其是在治疗的早期。",
          "start_idx": 0,
          "end_idx": 89,
          "entities": [
            {
              "entity_id": "T175",
              "entity": "别嘌醇",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 9,
              "entity_en": "Allopurinol"
            },
            {
              "entity_id": "T176",
              "entity": "血尿酸",
              "entity_type": "Test_items",
              "start_idx": 36,
              "end_idx": 39,
              "entity_en": "Serum uric acid"
            },
            {
              "entity_id": "T177",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 56,
              "end_idx": 58,
              "entity_en": "gout"
            },
            {
              "entity_id": "T178",
              "entity": "秋水仙碱",
              "entity_type": "Drug",
              "start_idx": 68,
              "end_idx": 72,
              "entity_en": "Colchicine"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R61",
              "head_entity_id": "T178",
              "tail_entity_id": "T177"
            }
          ],
          "sentence_en": "Note: ① The serious adverse reactions of allopurinol are related to the dose used. When the minimum effective dose can achieve the target blood uric acid level, try not to increase the dose. ② When controlling acute gout attacks, it is recommended to use colchicine or other anti-inflammatory drugs at the same time, especially in the early stage of treatment."
        }
      ],
      "paragraph_en": "Note: ① The serious adverse reactions of allopurinol are related to the dose used. When the minimum effective dose can achieve the target blood uric acid level, try not to increase the dose. ② When controlling acute gout attacks, it is recommended to use colchicine or other anti-inflammatory drugs at the same time, especially in the early stage of treatment."
    },
    {
      "paragraph_id": "32",
      "paragraph": "不良反应：包括胃肠道症状、皮疹、肝功能损害、骨髓抑制等，应密切监测。偶有发生严重的“别嘌醇超敏反应综合征”，应予以重视和积极处理。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "不良反应：包括胃肠道症状、皮疹、肝功能损害、骨髓抑制等，应密切监测。",
          "start_idx": 0,
          "end_idx": 34,
          "entities": [
            {
              "entity_id": "T179",
              "entity": "胃肠道症状",
              "entity_type": "ADE",
              "start_idx": 7,
              "end_idx": 12,
              "entity_en": "Gastrointestinal symptoms"
            },
            {
              "entity_id": "T180",
              "entity": "皮疹",
              "entity_type": "ADE",
              "start_idx": 13,
              "end_idx": 15,
              "entity_en": "rash"
            },
            {
              "entity_id": "T181",
              "entity": "肝功能损害",
              "entity_type": "ADE",
              "start_idx": 16,
              "end_idx": 21,
              "entity_en": "Liver impairment"
            },
            {
              "entity_id": "T182",
              "entity": "骨髓抑制",
              "entity_type": "ADE",
              "start_idx": 22,
              "end_idx": 26,
              "entity_en": "Bone marrow suppression"
            }
          ],
          "relations": [],
          "sentence_en": "Adverse reactions: including gastrointestinal symptoms, rash, liver function damage, bone marrow suppression, etc., should be closely monitored."
        },
        {
          "sentence_id": "1",
          "sentence": "偶有发生严重的“别嘌醇超敏反应综合征”，应予以重视和积极处理。",
          "start_idx": 34,
          "end_idx": 65,
          "entities": [
            {
              "entity_id": "T183",
              "entity": "别嘌醇超敏反应综合征",
              "entity_type": "ADE",
              "start_idx": 8,
              "end_idx": 18,
              "entity_en": "Allopurinol hypersensitivity syndrome"
            }
          ],
          "relations": [],
          "sentence_en": "Severe \"allopurinol hypersensitivity syndrome\" occasionally occurs and should be taken seriously and actively treated."
        }
      ],
      "paragraph_en": "Adverse reactions: including gastrointestinal symptoms, rash, liver damage, bone marrow suppression, etc., should be closely monitored. Occasionally, severe \"allopurinol hypersensitivity syndrome\" occurs, which should be taken seriously and actively treated."
    },
    {
      "paragraph_id": "33",
      "paragraph": "禁忌证：对别嘌醇过敏、严重肝肾功能不全和明显血细胞低下者、孕妇、有可能怀孕妇女以及哺乳期妇女。禁用于正在接受硫唑嘌呤治疗的患者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "禁忌证：对别嘌醇过敏、严重肝肾功能不全和明显血细胞低下者、孕妇、有可能怀孕妇女以及哺乳期妇女。",
          "start_idx": 0,
          "end_idx": 47,
          "entities": [
            {
              "entity_id": "T184",
              "entity": "肝肾功能不全",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 19,
              "entity_en": "Liver and kidney dysfunction"
            },
            {
              "entity_id": "T185",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 13,
              "end_idx": 14,
              "entity_en": "liver"
            },
            {
              "entity_id": "T186",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 14,
              "end_idx": 15,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T188",
              "entity": "别嘌醇过敏",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 10,
              "entity_en": "Allergy to allopurinol"
            },
            {
              "entity_id": "T189",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 11,
              "end_idx": 13,
              "entity_en": "serious"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R62",
              "head_entity_id": "T185",
              "tail_entity_id": "T184"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R63",
              "head_entity_id": "T186",
              "tail_entity_id": "T184"
            }
          ],
          "sentence_en": "Contraindications: Allergy to allopurinol, severe liver and kidney dysfunction and obvious low blood cells, pregnant women, women who may become pregnant and breastfeeding women."
        },
        {
          "sentence_id": "1",
          "sentence": "禁用于正在接受硫唑嘌呤治疗的患者。",
          "start_idx": 47,
          "end_idx": 64,
          "entities": [
            {
              "entity_id": "T187",
              "entity": "硫唑嘌呤",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 11,
              "entity_en": "Azathioprine"
            }
          ],
          "relations": [],
          "sentence_en": "It is contraindicated in patients receiving azathioprine."
        }
      ],
      "paragraph_en": "Contraindications: Allergy to allopurinol, severe hepatic and renal insufficiency and significant blood cell deficiency, pregnant women, women who may become pregnant and breastfeeding women. Contraindicated in patients receiving azathioprine treatment."
    },
    {
      "paragraph_id": "34",
      "paragraph": "密切监测别嘌醇的超敏反应。别嘌醇的超敏反应主要发生在最初使用的几个月内，最常见的是剥脱性皮炎。使用噻嗪类利尿剂及肾功能不全是发生超敏反应的危险因素。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "密切监测别嘌醇的超敏反应。别嘌醇的超敏反应主要发生在最初使用的几个月内，最常见的是剥脱性皮炎。使用噻嗪类利尿剂及肾功能不全是发生超敏反应的危险因素。",
          "start_idx": 0,
          "end_idx": 74,
          "entities": [
            {
              "entity_id": "T190",
              "entity": "别嘌醇",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "Allopurinol"
            },
            {
              "entity_id": "T191",
              "entity": "别嘌醇",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 16,
              "entity_en": "Allopurinol"
            },
            {
              "entity_id": "T192",
              "entity": "剥脱性皮炎",
              "entity_type": "ADE",
              "start_idx": 41,
              "end_idx": 46,
              "entity_en": "Exfoliative dermatitis"
            },
            {
              "entity_id": "T193",
              "entity": "噻嗪类利尿剂",
              "entity_type": "Drug",
              "start_idx": 49,
              "end_idx": 55,
              "entity_en": "Thiazide diuretics"
            },
            {
              "entity_id": "T194",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 56,
              "end_idx": 61,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T195",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 56,
              "end_idx": 57,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T196",
              "entity": "超敏反应",
              "entity_type": "ADE",
              "start_idx": 8,
              "end_idx": 12,
              "entity_en": "Hypersensitivity reactions"
            },
            {
              "entity_id": "T197",
              "entity": "超敏反应",
              "entity_type": "ADE",
              "start_idx": 17,
              "end_idx": 21,
              "entity_en": "Hypersensitivity reactions"
            },
            {
              "entity_id": "T198",
              "entity": "超敏反应",
              "entity_type": "ADE",
              "start_idx": 64,
              "end_idx": 68,
              "entity_en": "Hypersensitivity reactions"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R64",
              "head_entity_id": "T196",
              "tail_entity_id": "T190"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R65",
              "head_entity_id": "T192",
              "tail_entity_id": "T191"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R66",
              "head_entity_id": "T197",
              "tail_entity_id": "T191"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R67",
              "head_entity_id": "T198",
              "tail_entity_id": "T193"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R68",
              "head_entity_id": "T195",
              "tail_entity_id": "T194"
            }
          ],
          "sentence_en": "Closely monitor for hypersensitivity reactions to allopurinol. Hypersensitivity reactions to allopurinol occur primarily within the first few months of use, most commonly exfoliative dermatitis. Use of thiazide diuretics and renal insufficiency are risk factors for hypersensitivity reactions."
        }
      ],
      "paragraph_en": "Closely monitor for hypersensitivity reactions to allopurinol. Hypersensitivity reactions to allopurinol occur primarily within the first few months of use, with exfoliative dermatitis being the most common. Use of thiazide diuretics and renal insufficiency are risk factors for hypersensitivity reactions."
    },
    {
      "paragraph_id": "35",
      "paragraph": "对于特定人群(3期或3期以上CKD的朝鲜人、所有中国汉族和泰国人)，其HLA-B*5801等位基因频率较高，HLA-B*5801阳性个体发生严重别嘌醇超敏反应危险性极高。因此，HLA-B*5801阳性的患者忌用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "对于特定人群(3期或3期以上CKD的朝鲜人、所有中国汉族和泰国人)，其HLA-B*5801等位基因频率较高，HLA-B*5801阳性个体发生严重别嘌醇超敏反应危险性极高。",
          "start_idx": 0,
          "end_idx": 85,
          "entities": [
            {
              "entity_id": "T199",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 14,
              "end_idx": 17,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T200",
              "entity": "HLA-B*5801",
              "entity_type": "Test_items",
              "start_idx": 54,
              "end_idx": 64,
              "entity_en": "HLA-B*5801"
            },
            {
              "entity_id": "T201",
              "entity": "阳性",
              "entity_type": "Test_Value",
              "start_idx": 64,
              "end_idx": 66,
              "entity_en": "Positive"
            },
            {
              "entity_id": "T202",
              "entity": "别嘌醇",
              "entity_type": "Drug",
              "start_idx": 72,
              "end_idx": 75,
              "entity_en": "Allopurinol"
            },
            {
              "entity_id": "T205",
              "entity": "超敏反应",
              "entity_type": "ADE",
              "start_idx": 75,
              "end_idx": 79,
              "entity_en": "Hypersensitivity reactions"
            },
            {
              "entity_id": "T206",
              "entity": "3期或3期以上",
              "entity_type": "Class",
              "start_idx": 7,
              "end_idx": 14,
              "entity_en": "3 or more phases"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R69",
              "head_entity_id": "T206",
              "tail_entity_id": "T199"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R70",
              "head_entity_id": "T205",
              "tail_entity_id": "T202"
            }
          ],
          "sentence_en": "For specific populations (Koreans with CKD stage 3 or above, all Han Chinese, and Thais), the frequency of the HLA-B*5801 allele is relatively high, and HLA-B*5801-positive individuals are at extremely high risk of developing severe allopurinol hypersensitivity reactions."
        },
        {
          "sentence_id": "1",
          "sentence": "因此，HLA-B*5801阳性的患者忌用。",
          "start_idx": 85,
          "end_idx": 106,
          "entities": [
            {
              "entity_id": "T203",
              "entity": "HLA-B*5801",
              "entity_type": "Test_items",
              "start_idx": 3,
              "end_idx": 13,
              "entity_en": "HLA-B*5801"
            },
            {
              "entity_id": "T204",
              "entity": "阳性",
              "entity_type": "Test_Value",
              "start_idx": 13,
              "end_idx": 15,
              "entity_en": "Positive"
            }
          ],
          "relations": [],
          "sentence_en": "Therefore, it is contraindicated in patients with HLA-B*5801 positive status."
        }
      ],
      "paragraph_en": "For certain populations (Koreans with CKD stage 3 or above, all Han Chinese, and Thais), the frequency of the HLA-B*5801 allele is high, and HLA-B*5801-positive individuals are at high risk of severe allopurinol hypersensitivity reactions. Therefore, patients with HLA-B*5801 positive status should not use the drug."
    },
    {
      "paragraph_id": "36",
      "paragraph": "(2)非布司他：适用于痛风患者HUA的长期治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)非布司他：适用于痛风患者HUA的长期治疗。",
          "start_idx": 0,
          "end_idx": 24,
          "entities": [
            {
              "entity_id": "T207",
              "entity": "非布司他",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 7,
              "entity_en": "Febuxostat"
            },
            {
              "entity_id": "T208",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 13,
              "entity_en": "gout"
            },
            {
              "entity_id": "T209",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 15,
              "end_idx": 18,
              "entity_en": "HUA"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R71",
              "head_entity_id": "T207",
              "tail_entity_id": "T208"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R72",
              "head_entity_id": "T207",
              "tail_entity_id": "T209"
            }
          ],
          "sentence_en": "(2) Febuxostat: Suitable for the long-term treatment of HUA in patients with gout."
        }
      ],
      "paragraph_en": "(2) Febuxostat: Suitable for the long-term treatment of HUA in patients with gout."
    },
    {
      "paragraph_id": "37",
      "paragraph": "用法及用量：①口服推荐剂量为40mg或80mg，每日1次。推荐起始剂量为40mg，每日1次。若2周后，血尿酸水平仍不低于360μmol/L，建议剂量增至80mg，每日1次。②给药时，无需考虑食物和抗酸剂的影响。③轻、中度肾功能不全(eGFR30~89ml/min)的患者无需调整剂量。④对于CKD4期及以上患者，已有多项研究示非布司他的有效性及安全性，建议起始剂量为20mg，每日1次。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "用法及用量：①口服推荐剂量为40mg或80mg，每日1次。",
          "start_idx": 0,
          "end_idx": 29,
          "entities": [
            {
              "entity_id": "T210",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 7,
              "end_idx": 9,
              "entity_en": "oral"
            },
            {
              "entity_id": "T211",
              "entity": "40mg或80mg",
              "entity_type": "Amount",
              "start_idx": 14,
              "end_idx": 23,
              "entity_en": "40 mg or 80 mg"
            },
            {
              "entity_id": "T212",
              "entity": "每日1次",
              "entity_type": "Frequency",
              "start_idx": 24,
              "end_idx": 28,
              "entity_en": "1 time per day"
            }
          ],
          "relations": [],
          "sentence_en": "Usage and dosage: ① The recommended oral dose is 40 mg or 80 mg, once a day."
        },
        {
          "sentence_id": "1",
          "sentence": "推荐起始剂量为40mg，每日1次。若2周后，血尿酸水平仍不低于360μmol/L，建议剂量增至80mg，每日1次。②给药时，无需考虑食物和抗酸剂的影响。③轻、中度肾功能不全(eGFR30~89ml/min)的患者无需调整剂量。④对于CKD4期及以上患者，已有多项研究示非布司他的有效性及安全性，建议起始剂量为20mg，每日1次。",
          "start_idx": 29,
          "end_idx": 193,
          "entities": [
            {
              "entity_id": "T213",
              "entity": "起始剂量为40mg",
              "entity_type": "Amount",
              "start_idx": 2,
              "end_idx": 11,
              "entity_en": "The starting dose is 40 mg"
            },
            {
              "entity_id": "T214",
              "entity": "每日1次",
              "entity_type": "Frequency",
              "start_idx": 12,
              "end_idx": 16,
              "entity_en": "1 time per day"
            },
            {
              "entity_id": "T215",
              "entity": "血尿酸",
              "entity_type": "Test_items",
              "start_idx": 22,
              "end_idx": 25,
              "entity_en": "Serum uric acid"
            },
            {
              "entity_id": "T216",
              "entity": "不低于360μmol/L",
              "entity_type": "Test_Value",
              "start_idx": 28,
              "end_idx": 40,
              "entity_en": "Not less than 360 μmol/L"
            },
            {
              "entity_id": "T217",
              "entity": "80mg",
              "entity_type": "Amount",
              "start_idx": 47,
              "end_idx": 51,
              "entity_en": "80mg"
            },
            {
              "entity_id": "T218",
              "entity": "每日1次",
              "entity_type": "Frequency",
              "start_idx": 52,
              "end_idx": 56,
              "entity_en": "1 time per day"
            },
            {
              "entity_id": "T219",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 81,
              "end_idx": 86,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T220",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 81,
              "end_idx": 82,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T221",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 87,
              "end_idx": 91,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T222",
              "entity": "30~89ml/min",
              "entity_type": "Test_Value",
              "start_idx": 91,
              "end_idx": 102,
              "entity_en": "30~89ml/min"
            },
            {
              "entity_id": "T223",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 116,
              "end_idx": 119,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T224",
              "entity": "4期",
              "entity_type": "Class",
              "start_idx": 119,
              "end_idx": 121,
              "entity_en": "4th phase"
            },
            {
              "entity_id": "T225",
              "entity": "非布司他",
              "entity_type": "Drug",
              "start_idx": 134,
              "end_idx": 138,
              "entity_en": "Febuxostat"
            },
            {
              "entity_id": "T226",
              "entity": "起始剂量为20mg",
              "entity_type": "Amount",
              "start_idx": 149,
              "end_idx": 158,
              "entity_en": "The starting dose is 20 mg"
            },
            {
              "entity_id": "T227",
              "entity": "每日1次",
              "entity_type": "Frequency",
              "start_idx": 159,
              "end_idx": 163,
              "entity_en": "1 time per day"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R73",
              "head_entity_id": "T220",
              "tail_entity_id": "T219"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R74",
              "head_entity_id": "T221",
              "tail_entity_id": "T219"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R75",
              "head_entity_id": "T224",
              "tail_entity_id": "T223"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R76",
              "head_entity_id": "T225",
              "tail_entity_id": "T223"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R77",
              "head_entity_id": "T227",
              "tail_entity_id": "T225"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R78",
              "head_entity_id": "T226",
              "tail_entity_id": "T225"
            }
          ],
          "sentence_en": "The recommended starting dose is 40 mg, once a day. If the blood uric acid level is still not less than 360 μmol/L after 2 weeks, the recommended dose is increased to 80 mg, once a day. ② When administering, there is no need to consider the effects of food and antacids. ③ Patients with mild to moderate renal insufficiency (eGFR30~89ml/min) do not need to adjust the dose. ④ For patients with CKD stage 4 and above, many studies have shown the effectiveness and safety of febuxostat. The recommended starting dose is 20 mg, once a day."
        }
      ],
      "paragraph_en": "Usage and dosage: ① The recommended oral dose is 40 mg or 80 mg, once a day. The recommended starting dose is 40 mg, once a day. If the blood uric acid level is still not less than 360 μmol/L after 2 weeks, the recommended dose is increased to 80 mg, once a day. ② When administering, there is no need to consider the effects of food and antacids. ③ Patients with mild to moderate renal insufficiency (eGFR30~89ml/min) do not need to adjust the dose. ④ For patients with CKD stage 4 and above, many studies have shown the effectiveness and safety of febuxostat. The recommended starting dose is 20 mg, once a day."
    },
    {
      "paragraph_id": "38",
      "paragraph": "不良反应：主要有肝功能异常、恶心、关节痛、皮疹。数项研究显示非布司他的不良反应发生率低于别嘌醇。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "不良反应：主要有肝功能异常、恶心、关节痛、皮疹。",
          "start_idx": 0,
          "end_idx": 24,
          "entities": [
            {
              "entity_id": "T228",
              "entity": "肝功能异常",
              "entity_type": "ADE",
              "start_idx": 8,
              "end_idx": 13,
              "entity_en": "Abnormal liver function"
            },
            {
              "entity_id": "T229",
              "entity": "恶心",
              "entity_type": "ADE",
              "start_idx": 14,
              "end_idx": 16,
              "entity_en": "nausea"
            },
            {
              "entity_id": "T230",
              "entity": "关节痛",
              "entity_type": "ADE",
              "start_idx": 17,
              "end_idx": 20,
              "entity_en": "Joint pain"
            },
            {
              "entity_id": "T231",
              "entity": "皮疹",
              "entity_type": "ADE",
              "start_idx": 21,
              "end_idx": 23,
              "entity_en": "rash"
            }
          ],
          "relations": [],
          "sentence_en": "Adverse reactions: mainly abnormal liver function, nausea, joint pain, and rash."
        },
        {
          "sentence_id": "1",
          "sentence": "数项研究显示非布司他的不良反应发生率低于别嘌醇。",
          "start_idx": 24,
          "end_idx": 48,
          "entities": [
            {
              "entity_id": "T232",
              "entity": "非布司他",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 10,
              "entity_en": "Febuxostat"
            },
            {
              "entity_id": "T233",
              "entity": "别嘌醇",
              "entity_type": "Drug",
              "start_idx": 20,
              "end_idx": 23,
              "entity_en": "Allopurinol"
            }
          ],
          "relations": [],
          "sentence_en": "Several studies have shown that febuxostat has a lower incidence of adverse reactions than allopurinol."
        }
      ],
      "paragraph_en": "Adverse reactions: mainly abnormal liver function, nausea, joint pain, and rash. Several studies have shown that the incidence of adverse reactions of febuxostat is lower than that of allopurinol."
    },
    {
      "paragraph_id": "39",
      "paragraph": "禁忌证：本品禁用于正在接受硫唑嘌呤、巯嘌呤治疗的患者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "禁忌证：本品禁用于正在接受硫唑嘌呤、巯嘌呤治疗的患者。",
          "start_idx": 0,
          "end_idx": 27,
          "entities": [
            {
              "entity_id": "T234",
              "entity": "硫唑嘌呤",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 17,
              "entity_en": "Azathioprine"
            },
            {
              "entity_id": "T235",
              "entity": "巯嘌呤",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 21,
              "entity_en": "Mercaptopurine"
            }
          ],
          "relations": [],
          "sentence_en": "Contraindications: This product is contraindicated in patients receiving azathioprine or mercaptopurine treatment."
        }
      ],
      "paragraph_en": "Contraindications: This product is contraindicated in patients receiving azathioprine or mercaptopurine treatment."
    },
    {
      "paragraph_id": "40",
      "paragraph": "注意事项：在服用非布司他的初期，可见痛风发作频率增加。源于血尿酸浓度降低，导致组织中沉积的尿酸盐动员。为预防治疗初期的痛风发作，建议同时服用非甾体类抗炎药或秋水仙碱。在非布司他治疗期间，若痛风发作，无需中止非布司他治疗。应根据患者的具体情况进行适当调整。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "注意事项：在服用非布司他的初期，可见痛风发作频率增加。源于血尿酸浓度降低，导致组织中沉积的尿酸盐动员。为预防治疗初期的痛风发作，建议同时服用非甾体类抗炎药或秋水仙碱。在非布司他治疗期间，若痛风发作，无需中止非布司他治疗。",
          "start_idx": 0,
          "end_idx": 110,
          "entities": [
            {
              "entity_id": "T236",
              "entity": "非布司他",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 12,
              "entity_en": "Febuxostat"
            },
            {
              "entity_id": "T237",
              "entity": "痛风发作频率增加",
              "entity_type": "ADE",
              "start_idx": 18,
              "end_idx": 26,
              "entity_en": "Increased frequency of gout attacks"
            },
            {
              "entity_id": "T238",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 59,
              "end_idx": 61,
              "entity_en": "gout"
            },
            {
              "entity_id": "T239",
              "entity": "非甾体类抗炎药",
              "entity_type": "Drug",
              "start_idx": 70,
              "end_idx": 77,
              "entity_en": "Nonsteroidal anti-inflammatory drugs"
            },
            {
              "entity_id": "T240",
              "entity": "秋水仙碱",
              "entity_type": "Drug",
              "start_idx": 78,
              "end_idx": 82,
              "entity_en": "Colchicine"
            },
            {
              "entity_id": "T241",
              "entity": "非布司他",
              "entity_type": "Drug",
              "start_idx": 84,
              "end_idx": 88,
              "entity_en": "Febuxostat"
            },
            {
              "entity_id": "T242",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 94,
              "end_idx": 96,
              "entity_en": "gout"
            },
            {
              "entity_id": "T243",
              "entity": "非布司他",
              "entity_type": "Drug",
              "start_idx": 103,
              "end_idx": 107,
              "entity_en": "Febuxostat"
            },
            {
              "entity_id": "T244",
              "entity": "血尿酸浓度",
              "entity_type": "Test_items",
              "start_idx": 29,
              "end_idx": 34,
              "entity_en": "Serum uric acid concentration"
            },
            {
              "entity_id": "T245",
              "entity": "降低",
              "entity_type": "Test_Value",
              "start_idx": 34,
              "end_idx": 36,
              "entity_en": "reduce"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R79",
              "head_entity_id": "T237",
              "tail_entity_id": "T236"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R80",
              "head_entity_id": "T240",
              "tail_entity_id": "T238"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R81",
              "head_entity_id": "T239",
              "tail_entity_id": "T238"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R82",
              "head_entity_id": "T243",
              "tail_entity_id": "T242"
            }
          ],
          "sentence_en": "Note: In the early stage of taking Febuxostat, the frequency of gout attacks may increase. This is due to the decrease in blood uric acid concentration, which leads to the mobilization of urate deposited in tissues. To prevent gout attacks in the early stage of treatment, it is recommended to take nonsteroidal anti-inflammatory drugs or colchicine at the same time. During Febuxostat treatment, if gout attacks, there is no need to discontinue Febuxostat treatment."
        },
        {
          "sentence_id": "1",
          "sentence": "应根据患者的具体情况进行适当调整。",
          "start_idx": 110,
          "end_idx": 127,
          "entities": [],
          "relations": [],
          "sentence_en": "Appropriate adjustments should be made based on the patient's specific circumstances."
        }
      ],
      "paragraph_en": "Note: In the early stage of taking Febuxostat, the frequency of gout attacks may increase. This is due to the decrease in blood uric acid concentration, which leads to the mobilization of urate deposited in tissues. To prevent gout attacks in the early stage of treatment, it is recommended to take nonsteroidal anti-inflammatory drugs or colchicine at the same time. During the treatment of Febuxostat, if gout attacks, there is no need to discontinue Febuxostat treatment. Appropriate adjustments should be made according to the specific situation of the patient."
    },
    {
      "paragraph_id": "41",
      "paragraph": "针对高尿酸血症不同治疗方法的有效性和安全性比较的研究分析显示，与其他药物相比，非布司他具有更好的疗效和安全性。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "针对高尿酸血症不同治疗方法的有效性和安全性比较的研究分析显示，与其他药物相比，非布司他具有更好的疗效和安全性。",
          "start_idx": 0,
          "end_idx": 55,
          "entities": [
            {
              "entity_id": "T246",
              "entity": "高尿酸血症",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7,
              "entity_en": "Hyperuricemia"
            },
            {
              "entity_id": "T247",
              "entity": "非布司他",
              "entity_type": "Drug",
              "start_idx": 39,
              "end_idx": 43,
              "entity_en": "Febuxostat"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R83",
              "head_entity_id": "T247",
              "tail_entity_id": "T246"
            }
          ],
          "sentence_en": "A research analysis comparing the effectiveness and safety of different treatments for hyperuricemia showed that febuxostat has better efficacy and safety compared with other drugs."
        }
      ],
      "paragraph_en": "A research analysis comparing the effectiveness and safety of different treatments for hyperuricemia showed that febuxostat has better efficacy and safety compared with other drugs."
    },
    {
      "paragraph_id": "42",
      "paragraph": "2.促进尿酸排泄药物：若使用促排尿酸药物(包括苯溴马隆、丙磺舒)降低患者血尿酸水平，在治疗开始前和治疗过程中，要特别注意多饮水和使用碱化尿液的药物。若患者24h尿尿酸的排出量已经增加(>3.54mmol)或有泌尿系尿酸结石则应禁用此类药物，在溃疡病或肾功能不全者慎用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.促进尿酸排泄药物：若使用促排尿酸药物(包括苯溴马隆、丙磺舒)降低患者血尿酸水平，在治疗开始前和治疗过程中，要特别注意多饮水和使用碱化尿液的药物。若患者24h尿尿酸的排出量已经增加(>3.54mmol)或有泌尿系尿酸结石则应禁用此类药物，在溃疡病或肾功能不全者慎用。",
          "start_idx": 0,
          "end_idx": 134,
          "entities": [
            {
              "entity_id": "T248",
              "entity": "苯溴马隆",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 27,
              "entity_en": "Benzbromarone"
            },
            {
              "entity_id": "T249",
              "entity": "丙磺舒",
              "entity_type": "Drug",
              "start_idx": 28,
              "end_idx": 31,
              "entity_en": "Probenecid"
            },
            {
              "entity_id": "T250",
              "entity": "血尿酸",
              "entity_type": "Test_items",
              "start_idx": 36,
              "end_idx": 39,
              "entity_en": "Serum uric acid"
            },
            {
              "entity_id": "T251",
              "entity": "多饮水",
              "entity_type": "Treatment",
              "start_idx": 60,
              "end_idx": 63,
              "entity_en": "Drink plenty of water"
            },
            {
              "entity_id": "T252",
              "entity": "24h尿尿酸",
              "entity_type": "Test_items",
              "start_idx": 77,
              "end_idx": 83,
              "entity_en": "24h urine uric acid"
            },
            {
              "entity_id": "T253",
              "entity": "增加",
              "entity_type": "Test_Value",
              "start_idx": 89,
              "end_idx": 91,
              "entity_en": "Increase"
            },
            {
              "entity_id": "T254",
              "entity": ">3.54mmol",
              "entity_type": "Test_Value",
              "start_idx": 92,
              "end_idx": 101,
              "entity_en": ">3.54mmol"
            },
            {
              "entity_id": "T255",
              "entity": "泌尿系尿酸结石",
              "entity_type": "Disease",
              "start_idx": 104,
              "end_idx": 111,
              "entity_en": "Uric acid stones in the urinary tract"
            },
            {
              "entity_id": "T256",
              "entity": "溃疡病",
              "entity_type": "Disease",
              "start_idx": 121,
              "end_idx": 124,
              "entity_en": "Ulcers"
            },
            {
              "entity_id": "T257",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 125,
              "end_idx": 130,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T258",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 125,
              "end_idx": 126,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T259",
              "entity": "泌尿系",
              "entity_type": "Anatomy",
              "start_idx": 104,
              "end_idx": 107,
              "entity_en": "Urinary system"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R84",
              "head_entity_id": "T259",
              "tail_entity_id": "T255"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R85",
              "head_entity_id": "T258",
              "tail_entity_id": "T257"
            }
          ],
          "sentence_en": "2. Drugs that promote uric acid excretion: If drugs that promote uric acid excretion (including benzbromarone and probenecid) are used to lower the patient's blood uric acid level, special attention should be paid to drinking more water and using drugs that alkalinize urine before and during treatment. If the patient's 24-hour urine uric acid excretion has increased (>3.54mmol) or has urinary uric acid stones, such drugs should be prohibited. They should be used with caution in patients with ulcer disease or renal insufficiency."
        }
      ],
      "paragraph_en": "2. Drugs that promote uric acid excretion: If drugs that promote uric acid excretion (including benzbromarone and probenecid) are used to lower the patient's blood uric acid level, special attention should be paid to drinking more water and using drugs that alkalinize urine before and during treatment. If the patient's 24-hour urine uric acid excretion has increased (>3.54mmol) or has urinary uric acid stones, such drugs should be prohibited. They should be used with caution in patients with ulcer disease or renal insufficiency."
    },
    {
      "paragraph_id": "43",
      "paragraph": "(1)苯溴马隆：适用于原发性和继发性高尿酸血症。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)苯溴马隆：适用于原发性和继发性高尿酸血症。",
          "start_idx": 0,
          "end_idx": 24,
          "entities": [
            {
              "entity_id": "T260",
              "entity": "苯溴马隆",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 7,
              "entity_en": "Benzbromarone"
            },
            {
              "entity_id": "T261",
              "entity": "继发性高尿酸血症",
              "entity_type": "Disease",
              "start_idx": 15,
              "end_idx": 23,
              "entity_en": "Secondary hyperuricemia"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R86",
              "head_entity_id": "T260",
              "tail_entity_id": "T261"
            }
          ],
          "sentence_en": "(1) Benzbromarone: Suitable for primary and secondary hyperuricemia."
        }
      ],
      "paragraph_en": "(1) Benzbromarone: Suitable for primary and secondary hyperuricemia."
    },
    {
      "paragraph_id": "44",
      "paragraph": "用法及用量：成人起始剂量为每次口服50mg，每日1次，早餐后服用。成人及14岁以上患者每日50~100mg。轻、中度肾功能不全患者(eGFR>60ml/min)无须调整剂量。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "用法及用量：成人起始剂量为每次口服50mg，每日1次，早餐后服用。成人及14岁以上患者每日50~100mg。轻、中度肾功能不全患者(eGFR>60ml/min)无须调整剂量。",
          "start_idx": 0,
          "end_idx": 87,
          "entities": [
            {
              "entity_id": "T262",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 15,
              "end_idx": 17,
              "entity_en": "oral"
            },
            {
              "entity_id": "T263",
              "entity": "50mg",
              "entity_type": "Amount",
              "start_idx": 17,
              "end_idx": 21,
              "entity_en": "50mg"
            },
            {
              "entity_id": "T264",
              "entity": "每日1次",
              "entity_type": "Frequency",
              "start_idx": 22,
              "end_idx": 26,
              "entity_en": "1 time per day"
            },
            {
              "entity_id": "T265",
              "entity": "每日50~100mg",
              "entity_type": "Amount",
              "start_idx": 43,
              "end_idx": 53,
              "entity_en": "50–100 mg/day"
            },
            {
              "entity_id": "T266",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 58,
              "end_idx": 63,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T267",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 58,
              "end_idx": 59,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T268",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 66,
              "end_idx": 70,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T269",
              "entity": ">60ml/min",
              "entity_type": "Test_Value",
              "start_idx": 70,
              "end_idx": 79,
              "entity_en": ">60ml/min"
            },
            {
              "entity_id": "T270",
              "entity": "轻、中度",
              "entity_type": "Level",
              "start_idx": 54,
              "end_idx": 58,
              "entity_en": "Mild to moderate"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R87",
              "head_entity_id": "T268",
              "tail_entity_id": "T266"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R88",
              "head_entity_id": "T267",
              "tail_entity_id": "T266"
            }
          ],
          "sentence_en": "Usage and Dosage: The starting dose for adults is 50 mg orally once a day, taken after breakfast. Adults and patients over 14 years old take 50-100 mg daily. Patients with mild to moderate renal insufficiency (eGFR>60ml/min) do not need to adjust the dose."
        }
      ],
      "paragraph_en": "Usage and Dosage: The starting dose for adults is 50 mg orally once a day, taken after breakfast. Adults and patients over 14 years old take 50-100 mg daily. Patients with mild to moderate renal insufficiency (eGFR>60ml/min) do not need to adjust the dose."
    },
    {
      "paragraph_id": "45",
      "paragraph": "不良反应：可能出现肝损、胃肠不适、腹泻、皮疹、阳痿等，但较为少见。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "不良反应：可能出现肝损、胃肠不适、腹泻、皮疹、阳痿等，但较为少见。",
          "start_idx": 0,
          "end_idx": 33,
          "entities": [
            {
              "entity_id": "T271",
              "entity": "肝损",
              "entity_type": "ADE",
              "start_idx": 9,
              "end_idx": 11,
              "entity_en": "Liver damage"
            },
            {
              "entity_id": "T272",
              "entity": "胃肠不适",
              "entity_type": "ADE",
              "start_idx": 12,
              "end_idx": 16,
              "entity_en": "Gastrointestinal discomfort"
            },
            {
              "entity_id": "T273",
              "entity": "腹泻",
              "entity_type": "ADE",
              "start_idx": 17,
              "end_idx": 19,
              "entity_en": "diarrhea"
            },
            {
              "entity_id": "T274",
              "entity": "皮疹",
              "entity_type": "ADE",
              "start_idx": 20,
              "end_idx": 22,
              "entity_en": "rash"
            },
            {
              "entity_id": "T275",
              "entity": "阳痿",
              "entity_type": "ADE",
              "start_idx": 23,
              "end_idx": 25,
              "entity_en": "Impotence"
            }
          ],
          "relations": [],
          "sentence_en": "Adverse reactions: Liver damage, gastrointestinal discomfort, diarrhea, rash, impotence, etc. may occur, but they are relatively rare."
        }
      ],
      "paragraph_en": "Adverse reactions: Liver damage, gastrointestinal discomfort, diarrhea, rash, impotence, etc. may occur, but they are relatively rare."
    },
    {
      "paragraph_id": "46",
      "paragraph": "禁忌证：对本品中任何成分过敏者。严重肾功能损害者(eGFR<30ml/min)及有肾结石的患者，孕妇、有可能怀孕妇女以及哺乳期妇女。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "禁忌证：对本品中任何成分过敏者。",
          "start_idx": 0,
          "end_idx": 16,
          "entities": [],
          "relations": [],
          "sentence_en": "Contraindications: Allergic to any ingredient in this product."
        },
        {
          "sentence_id": "1",
          "sentence": "严重肾功能损害者(eGFR<30ml/min)及有肾结石的患者，孕妇、有可能怀孕妇女以及哺乳期妇女。",
          "start_idx": 16,
          "end_idx": 66,
          "entities": [
            {
              "entity_id": "T276",
              "entity": "肾功能损害",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7,
              "entity_en": "Renal impairment"
            },
            {
              "entity_id": "T277",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 2,
              "end_idx": 3,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T278",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 9,
              "end_idx": 13,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T279",
              "entity": "<30ml/min",
              "entity_type": "Test_Value",
              "start_idx": 13,
              "end_idx": 22,
              "entity_en": "<30ml/min"
            },
            {
              "entity_id": "T280",
              "entity": "肾结石",
              "entity_type": "Disease",
              "start_idx": 25,
              "end_idx": 28,
              "entity_en": "Kidney stones"
            },
            {
              "entity_id": "T281",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 25,
              "end_idx": 26,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T282",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 0,
              "end_idx": 2,
              "entity_en": "serious"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R89",
              "head_entity_id": "T278",
              "tail_entity_id": "T276"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R90",
              "head_entity_id": "T277",
              "tail_entity_id": "T276"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R91",
              "head_entity_id": "T281",
              "tail_entity_id": "T280"
            }
          ],
          "sentence_en": "Patients with severe renal impairment (eGFR < 30 ml/min) and kidney stones, pregnant women, women who may become pregnant, and breastfeeding women."
        }
      ],
      "paragraph_en": "Contraindications: Allergic to any ingredient in this product, patients with severe renal impairment (eGFR < 30 ml/min) and patients with kidney stones, pregnant women, women who may become pregnant, and breastfeeding women."
    },
    {
      "paragraph_id": "47",
      "paragraph": "注意事项：①治疗期间需大量饮水以增加尿量(治疗初期饮水量不得少于1500~2000ml/d)，避免排泄尿酸过多而在泌尿系统形成尿酸结石；2监测肝肾功能；③开始用药期间，建议给予碳酸氢钠或枸橼酸合剂，使患者的pH控制在6.2~6.9。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "注意事项：①治疗期间需大量饮水以增加尿量(治疗初期饮水量不得少于1500~2000ml/d)，避免排泄尿酸过多而在泌尿系统形成尿酸结石；2监测肝肾功能；③开始用药期间，建议给予碳酸氢钠或枸橼酸合剂，使患者的pH控制在6.2~6.9。",
          "start_idx": 0,
          "end_idx": 116,
          "entities": [
            {
              "entity_id": "T283",
              "entity": "大量饮水",
              "entity_type": "Treatment",
              "start_idx": 11,
              "end_idx": 15,
              "entity_en": "Drink plenty of water"
            },
            {
              "entity_id": "T284",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 51,
              "end_idx": 53,
              "entity_en": "Uric acid"
            },
            {
              "entity_id": "T285",
              "entity": "尿酸结石",
              "entity_type": "Disease",
              "start_idx": 63,
              "end_idx": 67,
              "entity_en": "Uric acid stones"
            },
            {
              "entity_id": "T286",
              "entity": "监测肝肾功能",
              "entity_type": "Test",
              "start_idx": 69,
              "end_idx": 75,
              "entity_en": "Monitor liver and kidney function"
            },
            {
              "entity_id": "T287",
              "entity": "碳酸氢钠",
              "entity_type": "Drug",
              "start_idx": 88,
              "end_idx": 92,
              "entity_en": "Sodium bicarbonate"
            },
            {
              "entity_id": "T288",
              "entity": "枸橼酸合剂",
              "entity_type": "Drug",
              "start_idx": 93,
              "end_idx": 98,
              "entity_en": "Citric acid mixture"
            }
          ],
          "relations": [],
          "sentence_en": "Note: 1. During treatment, patients need to drink plenty of water to increase urine output (the amount of water consumed in the initial stage of treatment should not be less than 1500-2000 ml/d) to avoid excessive excretion of uric acid and the formation of uric acid stones in the urinary system; 2. Monitor liver and kidney function; 3. During the initial medication, it is recommended to give sodium bicarbonate or citric acid mixture to control the patient's pH at 6.2-6.9."
        }
      ],
      "paragraph_en": "Note: 1. During treatment, patients need to drink plenty of water to increase urine output (the amount of water consumed in the initial stage of treatment should not be less than 1500-2000 ml/d) to avoid excessive excretion of uric acid and the formation of uric acid stones in the urinary system; 2. Monitor liver and kidney function; 3. During the initial medication, it is recommended to give sodium bicarbonate or citric acid mixture to control the patient's pH at 6.2-6.9."
    },
    {
      "paragraph_id": "48",
      "paragraph": "(2)丙磺舒：促排降尿酸治疗中，可选择丙磺舒作为单药疗法促排尿酸。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)丙磺舒：促排降尿酸治疗中，可选择丙磺舒作为单药疗法促排尿酸。",
          "start_idx": 0,
          "end_idx": 33,
          "entities": [
            {
              "entity_id": "T289",
              "entity": "丙磺舒",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 6,
              "entity_en": "Probenecid"
            },
            {
              "entity_id": "T290",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 10,
              "end_idx": 12,
              "entity_en": "Uric acid"
            },
            {
              "entity_id": "T291",
              "entity": "丙磺舒",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 22,
              "entity_en": "Probenecid"
            },
            {
              "entity_id": "T292",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 30,
              "end_idx": 32,
              "entity_en": "Uric acid"
            }
          ],
          "relations": [],
          "sentence_en": "(2) Probenecid: Probenecid can be used as a monotherapy to promote uric acid excretion in the treatment of uric acid lowering."
        }
      ],
      "paragraph_en": "(2) Probenecid: Probenecid can be used as a monotherapy to promote uric acid excretion in the treatment of uric acid lowering."
    },
    {
      "paragraph_id": "49",
      "paragraph": "用法及用量：成人起始剂量为每次口服0.25g，1日2次，1周后可增至每次0.5g，1日2次。根据临床表现及血和尿尿酸水平调整药物用量，原则上以最小有效量维持。丙磺舒的不良反应为肠胃不适、食欲下降、皮肤出疹，泌尿系尿酸结石等；当eGFR<30ml/min时无效，应避免使用。丙磺舒目前已较少临床使用，注意事项与苯溴马隆相似。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "用法及用量：成人起始剂量为每次口服0.25g，1日2次，1周后可增至每次0.5g，1日2次。根据临床表现及血和尿尿酸水平调整药物用量，原则上以最小有效量维持。丙磺舒的不良反应为肠胃不适、食欲下降、皮肤出疹，泌尿系尿酸结石等；当eGFR<30ml/min时无效，应避免使用。",
          "start_idx": 0,
          "end_idx": 136,
          "entities": [
            {
              "entity_id": "T293",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 15,
              "end_idx": 17,
              "entity_en": "oral"
            },
            {
              "entity_id": "T294",
              "entity": "0.25g",
              "entity_type": "Amount",
              "start_idx": 17,
              "end_idx": 22,
              "entity_en": "0.25g"
            },
            {
              "entity_id": "T295",
              "entity": "1日2次",
              "entity_type": "Frequency",
              "start_idx": 23,
              "end_idx": 27,
              "entity_en": "2 times a day"
            },
            {
              "entity_id": "T296",
              "entity": "每次0.5g",
              "entity_type": "Amount",
              "start_idx": 34,
              "end_idx": 40,
              "entity_en": "0.5g each time"
            },
            {
              "entity_id": "T297",
              "entity": "1日2次",
              "entity_type": "Frequency",
              "start_idx": 41,
              "end_idx": 45,
              "entity_en": "2 times a day"
            },
            {
              "entity_id": "T298",
              "entity": "血和尿尿酸",
              "entity_type": "Test_items",
              "start_idx": 53,
              "end_idx": 58,
              "entity_en": "Blood and urine uric acid"
            },
            {
              "entity_id": "T299",
              "entity": "丙磺舒",
              "entity_type": "Drug",
              "start_idx": 79,
              "end_idx": 82,
              "entity_en": "Probenecid"
            },
            {
              "entity_id": "T300",
              "entity": "肠胃不适",
              "entity_type": "ADE",
              "start_idx": 88,
              "end_idx": 92,
              "entity_en": "Gastrointestinal discomfort"
            },
            {
              "entity_id": "T301",
              "entity": "食欲下降",
              "entity_type": "ADE",
              "start_idx": 93,
              "end_idx": 97,
              "entity_en": "Decreased appetite"
            },
            {
              "entity_id": "T302",
              "entity": "皮肤出疹",
              "entity_type": "ADE",
              "start_idx": 98,
              "end_idx": 102,
              "entity_en": "Skin rash"
            },
            {
              "entity_id": "T303",
              "entity": "泌尿系尿酸结石",
              "entity_type": "ADE",
              "start_idx": 103,
              "end_idx": 110,
              "entity_en": "Uric acid stones in the urinary tract"
            },
            {
              "entity_id": "T304",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 113,
              "end_idx": 117,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T305",
              "entity": "<30ml/min",
              "entity_type": "Test_Value",
              "start_idx": 117,
              "end_idx": 126,
              "entity_en": "<30ml/min"
            },
            {
              "entity_id": "T308",
              "entity": "1周",
              "entity_type": "Duration",
              "start_idx": 28,
              "end_idx": 30,
              "entity_en": "1 week"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R92",
              "head_entity_id": "T300",
              "tail_entity_id": "T299"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R93",
              "head_entity_id": "T301",
              "tail_entity_id": "T299"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R94",
              "head_entity_id": "T302",
              "tail_entity_id": "T299"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R95",
              "head_entity_id": "T303",
              "tail_entity_id": "T299"
            }
          ],
          "sentence_en": "Usage and dosage: The starting dose for adults is 0.25g orally twice a day, which can be increased to 0.5g twice a day after one week. The dosage of the drug should be adjusted according to clinical manifestations and blood and urine uric acid levels. In principle, the minimum effective dose should be maintained. The adverse reactions of probenecid include gastrointestinal discomfort, decreased appetite, skin rash, urinary uric acid stones, etc.; it is ineffective when eGFR<30ml/min and should be avoided."
        },
        {
          "sentence_id": "1",
          "sentence": "丙磺舒目前已较少临床使用，注意事项与苯溴马隆相似。",
          "start_idx": 136,
          "end_idx": 161,
          "entities": [
            {
              "entity_id": "T306",
              "entity": "丙磺舒",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "Probenecid"
            },
            {
              "entity_id": "T307",
              "entity": "苯溴马隆",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 22,
              "entity_en": "Benzbromarone"
            }
          ],
          "relations": [],
          "sentence_en": "Probenecid is currently rarely used clinically, and the precautions are similar to those of benzbromarone."
        }
      ],
      "paragraph_en": "Usage and dosage: The starting dose for adults is 0.25g orally twice a day, which can be increased to 0.5g twice a day after one week. The dosage of the drug should be adjusted according to clinical manifestations and blood and urine uric acid levels. In principle, it should be maintained at the minimum effective dose. The adverse reactions of probenecid include gastrointestinal discomfort, decreased appetite, skin rash, uric acid stones in the urinary system, etc.; it is ineffective when eGFR<30ml/min and should be avoided. Probenecid is currently rarely used clinically, and the precautions are similar to those of benzbromarone."
    },
    {
      "paragraph_id": "50",
      "paragraph": "3.兼有降尿酸作用的其他药物：氯沙坦不但能降血压，同时能促进尿酸排泄。高血压患者，可考虑使用氯沙坦，但单独使用的降尿酸作用较弱。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.兼有降尿酸作用的其他药物：氯沙坦不但能降血压，同时能促进尿酸排泄。高血压患者，可考虑使用氯沙坦，但单独使用的降尿酸作用较弱。",
          "start_idx": 0,
          "end_idx": 64,
          "entities": [
            {
              "entity_id": "T309",
              "entity": "氯沙坦",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 18,
              "entity_en": "Losartan"
            },
            {
              "entity_id": "T310",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 35,
              "end_idx": 38,
              "entity_en": "hypertension"
            },
            {
              "entity_id": "T311",
              "entity": "氯沙坦",
              "entity_type": "Drug",
              "start_idx": 46,
              "end_idx": 49,
              "entity_en": "Losartan"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R96",
              "head_entity_id": "T311",
              "tail_entity_id": "T310"
            }
          ],
          "sentence_en": "3. Other drugs that also lower uric acid: Losartan can not only lower blood pressure, but also promote uric acid excretion. Hypertensive patients may consider using losartan, but its uric acid-lowering effect is weak when used alone."
        }
      ],
      "paragraph_en": "3. Other drugs that also lower uric acid: Losartan can not only lower blood pressure, but also promote uric acid excretion. Hypertensive patients may consider using losartan, but its uric acid-lowering effect is weak when used alone."
    },
    {
      "paragraph_id": "51",
      "paragraph": "有研究显示，非诺贝特与他汀类药物(尤其是阿托伐他汀)具有促进尿酸排泄作用。伴有高脂血症的患者，可考虑使用非诺贝特或他汀类药物，但两者的降尿酸作用都较弱。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "有研究显示，非诺贝特与他汀类药物(尤其是阿托伐他汀)具有促进尿酸排泄作用。伴有高脂血症的患者，可考虑使用非诺贝特或他汀类药物，但两者的降尿酸作用都较弱。",
          "start_idx": 0,
          "end_idx": 76,
          "entities": [
            {
              "entity_id": "T312",
              "entity": "非诺贝特",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 10,
              "entity_en": "Fenofibrate"
            },
            {
              "entity_id": "T313",
              "entity": "他汀类药物",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 16,
              "entity_en": "Statins"
            },
            {
              "entity_id": "T314",
              "entity": "阿托伐他汀",
              "entity_type": "Drug",
              "start_idx": 20,
              "end_idx": 25,
              "entity_en": "Atorvastatin"
            },
            {
              "entity_id": "T315",
              "entity": "高脂血症",
              "entity_type": "Disease",
              "start_idx": 39,
              "end_idx": 43,
              "entity_en": "Hyperlipidemia"
            },
            {
              "entity_id": "T316",
              "entity": "非诺贝特",
              "entity_type": "Drug",
              "start_idx": 52,
              "end_idx": 56,
              "entity_en": "Fenofibrate"
            },
            {
              "entity_id": "T317",
              "entity": "他汀类药物",
              "entity_type": "Drug",
              "start_idx": 57,
              "end_idx": 62,
              "entity_en": "Statins"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R97",
              "head_entity_id": "T316",
              "tail_entity_id": "T315"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R98",
              "head_entity_id": "T317",
              "tail_entity_id": "T315"
            }
          ],
          "sentence_en": "Studies have shown that fenofibrate and statins (especially atorvastatin) can promote uric acid excretion. Patients with hyperlipidemia may consider using fenofibrate or statins, but the uric acid-lowering effects of both are weak."
        }
      ],
      "paragraph_en": "Studies have shown that fenofibrate and statins (especially atorvastatin) can promote uric acid excretion. Patients with hyperlipidemia may consider using fenofibrate or statins, but the uric acid-lowering effects of both are weak."
    },
    {
      "paragraph_id": "52",
      "paragraph": "4.降尿酸药物的使用推荐意见：CKD患者HUA建议治疗流程见图2，各期CKD患者HUA的推荐治疗方案见表2。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.降尿酸药物的使用推荐意见：CKD患者HUA建议治疗流程见图2，各期CKD患者HUA的推荐治疗方案见表2。",
          "start_idx": 0,
          "end_idx": 54,
          "entities": [
            {
              "entity_id": "T318",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 15,
              "end_idx": 18,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T319",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 23,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T320",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 35,
              "end_idx": 38,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T321",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 40,
              "end_idx": 43,
              "entity_en": "HUA"
            }
          ],
          "relations": [],
          "sentence_en": "4. Recommendations for the use of uric acid-lowering drugs: The recommended treatment process for HUA in CKD patients is shown in Figure 2, and the recommended treatment options for HUA in patients with CKD at different stages are shown in Table 2."
        }
      ],
      "paragraph_en": "4. Recommendations for the use of uric acid-lowering drugs: The recommended treatment process for HUA in CKD patients is shown in Figure 2, and the recommended treatment options for HUA in patients with CKD at different stages are shown in Table 2."
    },
    {
      "paragraph_id": "53",
      "paragraph": "(三)药物相互作用",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(三)药物相互作用",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [],
          "relations": [],
          "sentence_en": "(III) Drug interactions"
        }
      ],
      "paragraph_en": "(III) Drug interactions"
    },
    {
      "paragraph_id": "54",
      "paragraph": "在应用降尿酸药物治疗CKD患者HUA时，应注意各药物之间的相互作用，详见表3。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "在应用降尿酸药物治疗CKD患者HUA时，应注意各药物之间的相互作用，详见表3。",
          "start_idx": 0,
          "end_idx": 39,
          "entities": [
            {
              "entity_id": "T322",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 10,
              "end_idx": 13,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T323",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 15,
              "end_idx": 18,
              "entity_en": "HUA"
            }
          ],
          "relations": [],
          "sentence_en": "When using uric acid-lowering drugs to treat HUA in CKD patients, attention should be paid to the interactions between the drugs, as shown in Table 3."
        }
      ],
      "paragraph_en": "When using uric acid-lowering drugs to treat HUA in CKD patients, attention should be paid to the interactions between the drugs, as shown in Table 3."
    },
    {
      "paragraph_id": "55",
      "paragraph": "综上，HUA是CKD发生、发展和预后的危险因素。充分重视和积极干预HUA将有利于CKD患者的预后。在临床实践工作中，应参考指南共识，并根据患者的具体情况实施个体化治疗，提高疗效，减少和防范药物的不良反应，改善患者的长期预后。我们期待在该领域有更多大样本、长随访的RCT研究为将来的临床指南的制定提供更多循证医学依据。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "综上，HUA是CKD发生、发展和预后的危险因素。",
          "start_idx": 0,
          "end_idx": 24,
          "entities": [
            {
              "entity_id": "T324",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 6,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T325",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "CKD"
            }
          ],
          "relations": [],
          "sentence_en": "In conclusion, HUA is a risk factor for the occurrence, development and prognosis of CKD."
        },
        {
          "sentence_id": "1",
          "sentence": "充分重视和积极干预HUA将有利于CKD患者的预后。",
          "start_idx": 24,
          "end_idx": 49,
          "entities": [
            {
              "entity_id": "T326",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 12,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T327",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 16,
              "end_idx": 19,
              "entity_en": "CKD"
            }
          ],
          "relations": [],
          "sentence_en": "Paying full attention to and actively intervening in HUA will be beneficial to the prognosis of CKD patients."
        },
        {
          "sentence_id": "2",
          "sentence": "在临床实践工作中，应参考指南共识，并根据患者的具体情况实施个体化治疗，提高疗效，减少和防范药物的不良反应，改善患者的长期预后。",
          "start_idx": 49,
          "end_idx": 112,
          "entities": [],
          "relations": [],
          "sentence_en": "In clinical practice, we should refer to the consensus guidelines and implement individualized treatment according to the patient's specific situation to improve efficacy, reduce and prevent adverse drug reactions, and improve the patient's long-term prognosis."
        },
        {
          "sentence_id": "3",
          "sentence": "我们期待在该领域有更多大样本、长随访的RCT研究为将来的临床指南的制定提供更多循证医学依据。",
          "start_idx": 112,
          "end_idx": 158,
          "entities": [],
          "relations": [],
          "sentence_en": "We look forward to more RCT studies with large samples and long follow-up in this field to provide more evidence-based medicine basis for the formulation of future clinical guidelines."
        }
      ],
      "paragraph_en": "In summary, HUA is a risk factor for the occurrence, development, and prognosis of CKD. Paying full attention to and actively intervening in HUA will be beneficial to the prognosis of CKD patients. In clinical practice, we should refer to the consensus of guidelines and implement individualized treatment according to the specific conditions of patients to improve efficacy, reduce and prevent adverse drug reactions, and improve the long-term prognosis of patients. We look forward to more large-sample, long-term follow-up RCT studies in this field to provide more evidence-based medicine for the formulation of future clinical guidelines."
    },
    {
      "paragraph_id": "27",
      "paragraph": "CKD患者HUA的降尿酸治疗，建议根据患者的伴随症状、合并症、并发症、肾功能情况和尿酸水平合理实施。对于伴有痛风的CKD患者，应在早期积极给予非药物治疗及降尿酸治疗。对于无症状的伴有HUA的CKD患者，男性血尿酸>420μmoI/L，女性血尿酸>360μmol/L，建议降尿酸治疗。降尿酸一线药物包括抑制尿酸生成药物(别嘌醇和非布司他)，促进尿酸排泄药物(苯溴马隆和丙磺舒)可为备选药物，治疗的血尿酸水平最低控制目标应<360μmol/L，在伴有严重痛风时建议控制目标<300μmol/L。不推荐长期维持血尿酸水平<180μmol/L。目前，对于无症状的伴有HUA的CKD患者，降尿酸的起始治疗阈值仍有争议，需要未来的进一步研究来确定。对于降尿酸治疗对肾脏的益处也需要更多高质、大样本的RCT来证实。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "CKD患者HUA的降尿酸治疗，建议根据患者的伴随症状、合并症、并发症、肾功能情况和尿酸水平合理实施。对于伴有痛风的CKD患者，应在早期积极给予非药物治疗及降尿酸治疗。对于无症状的伴有HUA的CKD患者，男性血尿酸>420μmoI/L，女性血尿酸>360μmol/L，建议降尿酸治疗。降尿酸一线药物包括抑制尿酸生成药物(别嘌醇和非布司他)，促进尿酸排泄药物(苯溴马隆和丙磺舒)可为备选药物，治疗的血尿酸水平最低控制目标应<360μmol/L，在伴有严重痛风时建议控制目标<300μmol/L。不推荐长期维持血尿酸水平<180μmol/L。目前，对于无症状的伴有HUA的CKD患者，降尿酸的起始治疗阈值仍有争议，需要未来的进一步研究来确定。",
          "start_idx": 0,
          "end_idx": 318,
          "entities": [
            {
              "entity_id": "T328",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 3,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T329",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 8,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T330",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 10,
              "end_idx": 12,
              "entity_en": "Uric acid"
            },
            {
              "entity_id": "T331",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 41,
              "end_idx": 43,
              "entity_en": "Uric acid"
            },
            {
              "entity_id": "T332",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 54,
              "end_idx": 56,
              "entity_en": "gout"
            },
            {
              "entity_id": "T333",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 57,
              "end_idx": 60,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T334",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 78,
              "end_idx": 80,
              "entity_en": "Uric acid"
            },
            {
              "entity_id": "T335",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 91,
              "end_idx": 94,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T336",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 95,
              "end_idx": 98,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T337",
              "entity": "男性血尿酸",
              "entity_type": "Test_items",
              "start_idx": 101,
              "end_idx": 106,
              "entity_en": "Male serum uric acid"
            },
            {
              "entity_id": "T338",
              "entity": ">420μmoI/L",
              "entity_type": "Test_Value",
              "start_idx": 106,
              "end_idx": 116,
              "entity_en": ">420μmoI/L"
            },
            {
              "entity_id": "T339",
              "entity": "女性血尿酸",
              "entity_type": "Test_items",
              "start_idx": 117,
              "end_idx": 122,
              "entity_en": "Female serum uric acid"
            },
            {
              "entity_id": "T340",
              "entity": ">360μmol/L",
              "entity_type": "Test_Value",
              "start_idx": 122,
              "end_idx": 132,
              "entity_en": ">360μmol/L"
            },
            {
              "entity_id": "T341",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 136,
              "end_idx": 138,
              "entity_en": "Uric acid"
            },
            {
              "entity_id": "T342",
              "entity": "别嘌醇",
              "entity_type": "Drug",
              "start_idx": 159,
              "end_idx": 162,
              "entity_en": "Allopurinol"
            },
            {
              "entity_id": "T343",
              "entity": "非布司他",
              "entity_type": "Drug",
              "start_idx": 163,
              "end_idx": 167,
              "entity_en": "Febuxostat"
            },
            {
              "entity_id": "T344",
              "entity": "抑制尿酸生成药物",
              "entity_type": "Drug",
              "start_idx": 150,
              "end_idx": 158,
              "entity_en": "Drugs that inhibit uric acid production"
            },
            {
              "entity_id": "T345",
              "entity": "促进尿酸排泄药物",
              "entity_type": "Drug",
              "start_idx": 169,
              "end_idx": 177,
              "entity_en": "Drugs that promote uric acid excretion"
            },
            {
              "entity_id": "T346",
              "entity": "苯溴马隆",
              "entity_type": "Drug",
              "start_idx": 178,
              "end_idx": 182,
              "entity_en": "Benzbromarone"
            },
            {
              "entity_id": "T347",
              "entity": "丙磺舒",
              "entity_type": "Drug",
              "start_idx": 183,
              "end_idx": 186,
              "entity_en": "Probenecid"
            },
            {
              "entity_id": "T348",
              "entity": "血尿酸",
              "entity_type": "Test_items",
              "start_idx": 197,
              "end_idx": 200,
              "entity_en": "Serum uric acid"
            },
            {
              "entity_id": "T349",
              "entity": "<360μmol/L",
              "entity_type": "Test_Value",
              "start_idx": 209,
              "end_idx": 219,
              "entity_en": "<360μmol/L"
            },
            {
              "entity_id": "T350",
              "entity": "痛风",
              "entity_type": "Disease",
              "start_idx": 225,
              "end_idx": 227,
              "entity_en": "gout"
            },
            {
              "entity_id": "T351",
              "entity": "<300μmol/L",
              "entity_type": "Test_Value",
              "start_idx": 234,
              "end_idx": 244,
              "entity_en": "<300 μmol/L"
            },
            {
              "entity_id": "T352",
              "entity": "血尿酸",
              "entity_type": "Test_items",
              "start_idx": 252,
              "end_idx": 255,
              "entity_en": "Serum uric acid"
            },
            {
              "entity_id": "T353",
              "entity": "<180μmol/L",
              "entity_type": "Test_Value",
              "start_idx": 257,
              "end_idx": 267,
              "entity_en": "<180μmol/L"
            },
            {
              "entity_id": "T354",
              "entity": "HUA",
              "entity_type": "Disease",
              "start_idx": 279,
              "end_idx": 282,
              "entity_en": "HUA"
            },
            {
              "entity_id": "T355",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 283,
              "end_idx": 286,
              "entity_en": "CKD"
            },
            {
              "entity_id": "T356",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 290,
              "end_idx": 292,
              "entity_en": "Uric acid"
            },
            {
              "entity_id": "T358",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 223,
              "end_idx": 225,
              "entity_en": "serious"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R99",
              "head_entity_id": "T330",
              "tail_entity_id": "T328"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R100",
              "head_entity_id": "T331",
              "tail_entity_id": "T328"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R101",
              "head_entity_id": "T330",
              "tail_entity_id": "T329"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R102",
              "head_entity_id": "T331",
              "tail_entity_id": "T329"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R103",
              "head_entity_id": "T334",
              "tail_entity_id": "T332"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R104",
              "head_entity_id": "T334",
              "tail_entity_id": "T333"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R105",
              "head_entity_id": "T337",
              "tail_entity_id": "T335"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R106",
              "head_entity_id": "T339",
              "tail_entity_id": "T335"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R107",
              "head_entity_id": "T341",
              "tail_entity_id": "T335"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R108",
              "head_entity_id": "T337",
              "tail_entity_id": "T336"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R109",
              "head_entity_id": "T339",
              "tail_entity_id": "T336"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R110",
              "head_entity_id": "T341",
              "tail_entity_id": "T336"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R111",
              "head_entity_id": "T342",
              "tail_entity_id": "T350"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R112",
              "head_entity_id": "T343",
              "tail_entity_id": "T350"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R113",
              "head_entity_id": "T344",
              "tail_entity_id": "T350"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R114",
              "head_entity_id": "T345",
              "tail_entity_id": "T350"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R115",
              "head_entity_id": "T346",
              "tail_entity_id": "T350"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R116",
              "head_entity_id": "T347",
              "tail_entity_id": "T350"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R117",
              "head_entity_id": "T348",
              "tail_entity_id": "T350"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R118",
              "head_entity_id": "T356",
              "tail_entity_id": "T354"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R119",
              "head_entity_id": "T356",
              "tail_entity_id": "T355"
            }
          ],
          "sentence_en": "It is recommended that uric acid-lowering treatment for HUA in CKD patients be implemented reasonably according to the patient's accompanying symptoms, comorbidities, complications, renal function and uric acid levels. For CKD patients with gout, non-drug treatment and uric acid-lowering treatment should be actively given in the early stage. For asymptomatic CKD patients with HUA, uric acid-lowering treatment is recommended for males with blood uric acid >420μmoI/L and females with blood uric acid >360μmol/L. First-line uric acid-lowering drugs include drugs that inhibit uric acid production (allopurinol and febuxostat), and drugs that promote uric acid excretion (benzbromarone and probenecid) can be alternative drugs. The minimum control target of blood uric acid level for treatment should be <360μmol/L, and the control target is recommended to be <300μmol/L when accompanied by severe gout. It is not recommended to maintain a blood uric acid level of <180μmol/L for a long time. At present, the initial treatment threshold for uric acid-lowering in asymptomatic CKD patients with HUA is still controversial and needs to be determined by further research in the future."
        },
        {
          "sentence_id": "1",
          "sentence": "对于降尿酸治疗对肾脏的益处也需要更多高质、大样本的RCT来证实。",
          "start_idx": 318,
          "end_idx": 350,
          "entities": [
            {
              "entity_id": "T357",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 3,
              "end_idx": 5,
              "entity_en": "Uric acid"
            }
          ],
          "relations": [],
          "sentence_en": "The benefits of uric acid-lowering therapy on the kidneys also need more high-quality, large-sample RCTs to confirm."
        }
      ],
      "paragraph_en": "It is recommended that uric acid-lowering treatment for HUA in CKD patients be implemented reasonably according to the patient's accompanying symptoms, comorbidities, complications, renal function and uric acid levels. For CKD patients with gout, non-drug treatment and uric acid-lowering treatment should be actively given in the early stage. For asymptomatic CKD patients with HUA, uric acid-lowering treatment is recommended for males with blood uric acid >420μmoI/L and females with blood uric acid >360μmol/L. First-line uric acid-lowering drugs include drugs that inhibit uric acid production (allopurinol and febuxostat), and drugs that promote uric acid excretion (benzbromarone and probenecid) can be alternative drugs. The minimum control target of blood uric acid level for treatment should be <360μmol/L, and the control target is recommended to be <300μmol/L when accompanied by severe gout. It is not recommended to maintain a blood uric acid level of <180μmol/L for a long time. At present, the initial treatment threshold for uric acid-lowering in asymptomatic CKD patients with HUA is still controversial and needs to be determined by further research in the future. The benefits of uric acid-lowering therapy on the kidneys also need more high-quality, large-sample RCTs to confirm."
    }
  ]
}